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The regulation of protein synthesis is an important aspect of the control of gene 
expression in neurons and is thought to contribute to neurologic diseases such as Fragile 
X mental retardation syndrome.  We demonstrate that several neuronal RNA-binding 
proteins implicated in human disease are associated with brain polyribosomes, namely 
the Nova and Hu paraneoplastic antigens and the Fragile X mental retardation protein.  
We use microarray analysis of polyribosomal mRNAs in knockout mouse models of 
these diseases to identify target mRNAs and analyze the translational profiles of mice 
lacking Nova-1 or FMRP.  The KH2 and RGG box RNA-binding domains of FMRP bind 
specific RNA motifs that form kissing complex and G-quartet structures, respectively.  
We find that the association of FMRP with polyribosomes in both mouse brain and 
human neuroblastoma cells is abrogated by competition with kissing complex RNA, but 
not by high-affinity G-quartet RNA.  In addition, the polyribosome associations of 
FMRP-interacting proteins FXR1 and FXR2, are specifically abrogated by competition 
with this kissing complex RNA.  FXR1 and FXR2 also bind kissing complex RNA via 
KH2, and they are competed off polyribosomes by kissing complex RNA even in the 
absence of FMRP.  Kissing complex RNA does not disrupt heterodimerization between 
FMRP and FXR1 or FXR2. We conclude that the mental retardation associated with the 
I304N mutation, and likely the Fragile-X syndrome more generally, may relate to a 
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CHAPTER I: INTRODUCTION 
 
Translational control in neurons 
Translation of messenger RNAs into functional proteins is the final step in the 
gene expression pathway.  As such, it represents a vital mechanism for control of protein 
levels in the cell.  Regulation of mRNA translation is relatively fast, lacking requirements 
for RNA transcription, processing, and nuclear export.  Instead, a previously established 
pool of mRNAs can be held in a translationally inactive state, ready to produce encoded 
proteins when necessary.  Furthermore, this mechanism may be restricted locally; 
translation of a particular pool of mRNAs in a specific subcellular area undergoes 
regulation unique to that subcellular location, such as an individual dendritic spine.  Tight 
control of translation is particularly necessary for neurons, since neuronal signaling 
mechanisms rely on a delicate balance of synaptic components for effective 
neurotransmission and memory formation.  Translational control can be achieved by both 
global and mRNA-specific mechanisms, and by interventions during translation initiation 
and/or elongation steps. As such, translational regulation represents a real-time strategy 
for cellular control of gene expression. (Gebauer and Hentze, 2004; Kindler et al., 2005; 
Moore, 2005; Wang and Tiedge, 2004) 
Global control of translation mainly involves modification of initiation factors.  A 
well-characterized example is that of cap-binding protein eIF4E availability.  Interaction 
of eIF4E with the scaffold protein eIF4G is required for cap-mediated recruitment of the 
43S ribosomal complex to an mRNA during initiation.  eIF4E-binding proteins (4E-BPs) 
compete with eIF4G for interaction with eIF4E, preventing recruitment of the 43S 
complex and resulting in translational inhibition.  However, activation of the insulin, 
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PI3K/Akt/mTOR and MAPK signaling pathways can phosphorylate 4E-BPs to enable 
interaction of eIF4E with eIF4G and initiation of translation (Gingras et al., 1999; 
Kelleher et al., 2004a; Kelleher et al., 2004b; Pause et al., 1994; Raught et al., 2000; 
Ruggero and Sonenberg, 2005; Treisman, 1996).  A second example of global 
translational repression occurs during cell death.  The apoptotic protein caspase-3 cleaves 
initiation factor eIF4G and poly(A)-binding protein (PABP) resulting in inhibition of 
initiation. (Bushell et al., 2000; Marissen et al., 2004)  A location-specific, global 
mechanism of translational repression can be found in the small, untranslated BC1 and 
BC200 RNAs, which are specifically targeted to dendrites in neurons.  BC1 inhibits 
translation of a reporter in Xenopus oocytes by interacting with both translation initiation 
factor eIF4A and PABP (Wang et al., 2005). 
Blockage of translational initiation factor recruitment is also a goal of some 
mRNA-specific regulatory mechanisms.  Sequence and structural elements in an mRNA 
such as the presence of a hairpin, internal ribosome entry site (IRES), or binding site for 
an RNA-binding protein can influence translational state.  The iron regulatory proteins 
IRP1 and IRP2 bind an iron-responsive element (IRE) in the 5’UTRs of the ferritin 
heavy- and light-chain mRNAs.  Protein binding to this stem-loop sequence hinders 43S 
complex recruitment by the cap-binding complex, thereby preventing translation 
initiation. (Gray and Hentze, 1994; Muckenthaler et al., 1998)  Other regulatory proteins 
can act as message-specific 4E-BPs.  The cytoplasmic element-binding protein (CEBP) 
binds a CPE sequence in the 3’UTR of target mRNAs.  It inhibits translation initiation by 
forming a complex with Maskin, a protein that binds to eIF4E and displaces eIF4G.  On 
phosphorylation by Aurora kinase, CEBP promotes polyadenylation of the mRNA and 
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dissociation of Maskin from eIF4E.  (Mendez and Richter, 2001)  During development of 
the Drosophila melanogaster embryo, Bicoid inhibits the translation of caudal mRNA by 
directly binding to both eIF4E and an element in the 3’UTR (Niessing et al., 2002).  In 
response to interferon-γ, ribosomal protein L13a is phosphorylated and released from the 
60S ribosomal subunit; it then binds to a sequence in the 3’UTR of ceruloplasmin mRNA 
and subsequently inhibits the initiation of translation (Mazumder et al., 2003).  The RNA-
binding proteins hnRNP K (heterogenous nuclear ribonucleoprotein K) and hnRNP E1 
bind to a CU-rich sequence known as the differentiation-control element (DICE) in the 
3’UTR of 15-lipoxygenase (LOX) mRNA.  hnRNP K and hnRNP E1 repress LOX 
translation by preventing 60S ribosomal subunit binding. (Ostareck et al., 2001; Ostareck 
et al., 1997; Ostareck-Lederer and Ostareck, 2004)  Zipcode binding protein 1 (ZBP1) 
binds to the 3’UTR of β-actin mRNA and is required for its translocation to sites of 
active actin polymerization (Eom et al., 2003; Farina et al., 2003; Oleynikov and Singer, 
2003; Tiruchinapalli et al., 2003).  Like hnRNP K, ZBP1 inhibits translation initiation by 
impairing the transition from a 48S complex to an 80S ribosome.  Translation of β-actin 
mRNA is activated by Src-dependent phosphorylation of ZBP1, which abrogates RNA-
binding ability (Huttelmaier et al., 2005).  As described above, most translational control 
mechanisms yet described act on the translational initiation pathway, and result in the 
inhibition of protein synthesis. 
Translational control can also be achieved through regulation of elongation rather 
than initiation.  NMDA receptor activation in rat brain synaptoneurosomes induces 
phosphorylation of elongation factor eEF2, a process that reduces the rate of peptide 
chain elongation.  This promotes a general decrease in protein translation, but an increase 
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in translation of abundant but poorly initiated mRNAs such as that encoding αCamK II.  
(Scheetz et al., 1997; Scheetz et al., 2000)  Translational regulation of the Drosophila 
oskar (osk) and nanos mRNAs seem to involve inhibition of both initiation and 
elongation. Initiation is inhibited by binding of Bruno to the 3’UTR of osk.  Bruno 
recruits a 4E-BP, Cup, which then prevents binding of eIF4E to eIF4G (Nakamura et al., 
2004)  Cup is also involved in translational repression of nanos by interaction with 
Smaug bound to the nanos 3’UTR (Nelson et al., 2004).  However, both osk and nanos 
mRNAs are associated with polyribosomes even when osk and nanos proteins do not 
accumulate, suggesting that there may be more than one means of repressing the 
translation of these mRNAs (Braat et al., 2004; Clark et al., 2000).  microRNAs 
(miRNAs) inhibit translation by partial base-pairing to target mRNAs, usually in the 
3’UTR (Hutvagner and Zamore, 2002).  The mechanism of this repression is largely 
unknown, but may involve inhibition of elongation, as translational repression of lin-14 
mRNA by lin-4 miRNA does not alter its association with polyribosomes (Olsen and 
Ambros, 1999). 
 Local control of translation is an important aspect of the regulation of gene 
expression.  Although originally studied in developmental processes in Xenopus and 
Drosophila, mRNA targeting and localization has become a key aspect of the current 
theory of activity-dependent synaptic modification. (Schuman et al., 2006; Wang and 
Tiedge, 2004)  In essence, for an mRNA to have a selective impact on a specific synapse, 
its transport must be correctly targeted to the translational area of that synapse, and either 
transport or translation of this mRNA must be regulated in a manner that can be altered 
by activity at that synapse.  It follows that locally translated messages should encode 
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proteins that are in use at the synapse, modify other proteins at the synapse, or serve as 
messengers to send signals back to other parts of the neuron. Many studies have shown 
that protein synthesis is required for long-lasting forms of behavioral and synaptic 
plasticity (Bailey et al., 1996; Mayford et al., 1996; Nguyen and Kandel, 1996).  
Evidence for this hypothesis includes localization of polyribosomes and associated 
membranous cisterns to sub-synaptic sites in dendrites (Gardiol et al., 1999; Steward, 
1983; Steward and Fass, 1983; Steward and Levy, 1982), assessments of the mRNA 
complement of dendritic processes (Eberwine, 1996; Eberwine et al., 2002; Eberwine et 
al., 2001; Miyashiro et al., 1994), protein synthesis in isolated synaptosomal preparations 
(Chicurel et al., 1993; Rao and Steward, 1991), translation of an mRNA construct 
transfected into an isolated dendrite (Crino and Eberwine, 1996), studies of 
polyadenylation-induced translation of the αCaMKII mRNA in synaptosome 
preparations after NMDA receptor activation (Huang et al., 2002), and the observation 
that polyribosomes redistribute to dendritic spines from dendritic shafts after induction of 
long-term potentiation (LTP) (Ostroff et al., 2002).  Investigation of the roles for neuron-
specific RNA-binding proteins in translational control may yield valuable clues for both 
synaptic physiology and human disease. 
 
Neurological disease and RNA-binding proteins: autoimmune-mediated 
Paraneoplastic neurologic degenerations (PNDs) are cancer-associated 
neurodegenerative disorders that are thought to arise when a neoplasm expresses a 
normally neuron-restricted protein.  Autoreactive antibodies and T cells are generated 
against the protein as an antigen of the tumor cell.  If the immune response is present in 
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the cerebrospinal fluid, the antigen may then be recognized in its normal location – a 
neuron.  The development of an immune response to the paraneoplastic antigen may 
benefit the patient in suppressing tumor growth, but may ultimately lead to loss of 
function of this protein in the neurons where it normally resides.  Such loss of function 
may result in neuronal death and/or severe neurologic impairment. (Albert et al., 2000; 
Albert et al., 1998; Albert and Darnell, 2004; Buckanovich et al., 1996; Darnell, 1996; 
Darnell and Posner, 2003; Musunuru and Darnell, 2001) 
It is interesting that a number of RNA-binding proteins (RBPs) have been found 
to be target antigens in a variety of autoimmune diseases.  The Nova family of RNA-
binding proteins (RBPs) was first discovered as target antigens of the neurodegenerative 
disorder, paraneoplastic opsoclonus-myoclonus ataxia (POMA).  POMA is most often 
found in association with tumors of the lung, breast and fallopian tubes.  Symptoms are 
characterized by a loss of inhibitory control of motor neurons in the brainstem and spinal 
cord, leading to rapid irregular eye movements (opsoclonus), muscle spasms 
(myoclonus), and a failure of muscular coordination (ataxia).(Buckanovich et al., 1993)  
The Hu family of proteins was identified as during the investigation of another PND, 
paraneoplastic encephalomyelopathy/sensory neuropathy (Hu syndrome).  Hu proteins 
contain three RNA-recognition motifs (RRMs) and are thought to be involved in RNA 
stability, export and translation. (Antic and Keene, 1998; Antic et al., 1999; Darnell and 
Posner, 2006; Levine et al., 1993) A novel RBP, termed GW182, has been identified as a 
target antigen using serum from a patient with ataxia and sensory polyneuropathy 
(Eystathioy et al., 2002).  GW182 is a cytoplasmic protein that is involved in miRNA 
mediated mRNA degradation in cytoplasmic processing bodies (Behm-Ansmant et al., 
 7 
2006; Jakymiw et al., 2005; Liu et al., 2005).  hnRNP A1, another RBP, is cross-reactive 
with the viral HTLV-tax protein in individuals with human T-lymphotrophic virus type 1-
associated myelopathy/tropical spastic paresis (HAM/TSP) (Levin et al., 2002).  These 
patients develop antibodies to neurons and have symptoms of progressive corticospinal 
tract damage (weakness, spasticity and pathological reflexes). These autoantibodies 
inhibit neuronal firing, and are targeted to epitopes within hnRNP A1 that include an 
RGG type RNA-binding domain, suggesting that this domain is important for normal 
function of hnRNP A1 (Lee et al., 2006).  While human autoimmune disorders have 
provided the means to identify many of these RBPs, and clues to their physiological 
functions in neurons, model organisms are required for further understanding of the 
pathophysiology of these diseases. 
 
Neurological disease and RNA binding proteins: loss-of-function mouse models  
Several RBPs have been knocked out in the mouse to create model systems for 
the study of human diseases.  The Nova family consists of two highly conserved genes, 
Nova-1 and Nova-2.  Expression of Nova-1 (commonly targeted in POMA, originally 
termed the Ri antigen) is expressed in the ventral spinal cord, brainstem, and deep nuclei 
of the cerebellum, as well as in discrete supratentorial regions such as the cingulum and 
amygdala.  Expression of Nova-2, an antigen targeted in POMA patients with dementia, 
is largely complementary to Nova-1, and is most prominently expressed in regions such 
as the cerebral and cerebellar cortices and dorsal spinal cord (Yang et al., 1998).  Nova-1 
null mice show action tremors and difficulty walking, symptoms similar to those of 
POMA patients.  Apoptotic death of motor neurons is seen in these mice and ultimately 
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the mice die at about 1-2 weeks of age.(Jensen et al., 2000a)  Nova-2 null mice have a 
lesser degree of ataxia and die at approximately 2-3 weeks of age. (Ule et al., 2003) 
In contrast to the severe phenotypes of the Nova-null mice, while there is a 
transient delay in neurite extension in mutant embryos, HuD-null pups are 
indistinguishable from their wild type littermates for the first several postnatal weeks. 
Adult animals, however, develop an abnormal hind-limb clasping reflex and show poor 
motor ability. (Akamatsu et al., 2005)  Thus, the importance of RBPs to neurologic 
disease is clear. 
 Fragile X syndrome (FXS) represents another neuropathology in which the 
mechanism of disease is thought to result from an alteration in translational regulation by 
an RNA-binding protein.  FXS is the most common heritable form of mental retardation 
in children, with an incidence of about 1 in 4000 males, and 1 in 8000 females.  The 
phenotype of FXS includes mild to severe cognitive deficits, attention-deficit 
hyperactivity disorder, autistic-like behavior, abnormal facial features such as a 
prominent jaw and large ears, macroorchidism in postpubescent males, and some 
connective tissue abnormalities. (Reviewed in Jin and Warren, 2003.)  Most cases of 
Fragile X syndrome are caused by an expansion in the CGG repeat tract located in the 
5’UTR of fragile X mental retardation 1 (FMR1) on the X chromosome (Fu et al., 1991; 
Oberle et al., 1991; Verkerk et al., 1991).  The expansion from a normal length of 7-54 
repeats to a length of over 230 repeats in affected individuals effectively silences the 
expression of FMRP, since the CGG tract is associated with increased methylation and 
chromatin deacetylation (Coffee et al., 1999; Hornstra et al., 1993; Oberle et al., 1986; 
Pieretti et al., 1991; Sutcliffe et al., 1992).  However, some fragile X patients have 
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intragenic deletions or nonsense mutations in FMR1 instead of a trinucleotide repeat 
expansion (Hirst et al., 1995; Lugenbeel et al., 1995; Meijer et al., 1994).  A single 
patient has been identified with a missense mutation, I304N, that results in a severe 
fragile X phenotype (De Boulle et al., 1993). 
FMRP shuttles between the nucleus and cytoplasm and has been localized to 
polyribosomes at synapses in neurons (Devys et al., 1993; Eberhart et al., 1996; Feng et 
al., 1997b; Sittler et al., 1996; Tamanini et al., 1999).  The presence of FMRP and its 
autosomal paralogs, FXR1 and FXR2, at the synapse has implications for its role in the 
cognitive phenotype of fragile X syndrome.  In fact, abnormally long dendritic spines 
have been noted in autopsy sections of brains from fragile X patients, and in brains for 
Fmr1 knockout mice (Comery et al., 1997; Greenough et al., 2001; Hinton et al., 1991; 
Irwin et al., 2000; Nimchinsky et al., 2001; Rudelli et al., 1985).  Fmr1 knockout mice 
have subtle defects in behavior and learning, as well as showing increased sensitivity to 
audiogenic epileptic seizures and increased anxiety (Musumeci et al., 2000; Oostra et al., 
1994; Peier et al., 2000).  Furthermore, metabotropic glutamate receptor (mGluR) 
activation in Fmr1 knockout mouse synaptoneurosomes does not produce the increase in 
protein synthesis that is seen in synaptoneurosomes from wild type mice (Greenough et 
al., 2001).  Finally, group I mGluR-dependent long-term depression (LTD) is increased in 
hippocampal slices of Fmr1 knockout mice and is dependent on the transient degradation 
of FMRP in wild type mice (Hou et al., 2006; Huber et al., 2002).  In Drosophila, a single 
ortholog, dfmr1 (also called dfxr), exists for all three mammalian FMRP family members. 
Dfmr1-mutant flies exhibit increased synaptic growth and branching at the neuromuscular 
junction, impaired coordinated behavior, arrhythmic circadian activity and reduced 
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courtship (Dockendorff et al., 2002; Inoue et al., 2002; Morales et al., 2002; Zhang et al., 
2001).  Activity-dependent synaptic modification depends in part on local protein 
synthesis in the dendrite (Steward and Schuman, 2003).  Since FMRP is associated with 
polyribosomes at synapses, and since the FMRP null phenotype includes cognitive 
impairment and synaptic abnormalities, FMRP may be involved in the regulation of local 
translation in neurons.  
 
KH domain proteins in RNA processing and regulation 
The Nova-1 and Nova-2 genes encode proteins that contain two tandem hnRNP 
K-homology (KH) RNA-binding domains followed by a spacer region of variable length 
and a third KH domain.  Nova-1 and Nova-2 are highly homologous, differing in the 
length of the spacer region.  The larger family of KH domain-containing RNA-binding 
proteins (RBPs) includes hnRNP K, which, like the Nova proteins, contains three KH 
domains in the same configuration.  FMRP, implicated in Fragile-X syndrome, contains 
two tandem KH domains and a third RNA-binding domain known as an RGG box (De 
Boulle et al., 1993; Pieretti et al., 1991).  Both hnRNP K and FMRP are thought to 
function in translational control: hnRNP K by binding a pyrimidine-rich element in the 
3’UTR and inhibiting translation initiation (Ostareck et al., 2001), and FMRP by 
associating with mRNAs on actively translating polyribosomes (Corbin et al., 1997; 
Khandjian et al., 1996; Khandjian et al., 2004; Laggerbauer et al., 2001; Stefani et al., 
2004).  Additional members of this family function in various aspects of RNA 
metabolism and regulation, including RNA stability and translational control (hnRNP 
E1/E2 and hnRNP K) (Kiledjian et al., 1995; Ostareck et al., 1997), subcellular 
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localization and translational inhibition (ZBP-1) (Farina et al., 2003; Huttelmaier et al., 
2005), and splicing (hnRNP K, KSRP and splicing factor 1) (Arning et al., 1996; Expert-
Bezancon et al., 2002). 
Our laboratory has shown that Nova-1 and Nova-2 influence alternative splice site 
choice by binding YCAY-rich sites in both intronic and exonic RNA.  Nova proteins 
regulate pre-mRNA splicing for a network of synaptic proteins, suggesting that this 
regulatory mechanism is critical for synaptic development and maintenance. (Dredge and 
Darnell, 2003; Dredge et al., 2005; Jensen et al., 2000a; Jensen et al., 2000b; Musunuru 
and Darnell, 2004; Ule et al., 2003; Ule et al., 2005b)  Nova-1 and Nova-2, like FMRP 
and hnRNP K, are found both in the nucleus and the cytoplasm (Eberhart et al., 1996; 
Michael et al., 1997).  Although the Nova proteins are predominantly nuclear, they are 
present in significant quantities in the cytoplasm, and Nova-1 has been co-localized with 
GlyRα2 mRNA in post-synaptic regions of the dendrite (Racca et al., submitted).  Since 
Nova proteins bind both coding and non-coding RNA sequences, it is reasonable to 
suggest that the Nova proteins may be multifunctional, perhaps regulating downstream 
events for messages that have undergone Nova-influenced alternative splicing.  For 
example, after influencing an alternative splicing decision in the nucleus, Nova may 
regulate the subcellular localization and/or the association with polyribosomes of a target 
mRNA. Alternately, the cytoplasmic role(s) of the Nova proteins may affect an entirely 
separate set of mRNAs than those affected by Nova’s splicing function.  Nova may bind 
to the 3’ UTR of a message in an analogous fashion to hnRNP K to regulate translation of 
a message during transport and until such a time when translation of that message is 
activated.  Conversely, Nova may promote association with polyribosomes and activation 
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of translation at the synapse upon receiving a hypothetical “activity-dependent” signal.  A 
third possibility is that Nova may be associated with an complex that inhibits translation 
in mRNA trafficking, but also remains bound to the 3’UTR of mRNAs associated with 
actively translating polyribosomes, perhaps serving as a scaffolding protein in this 
translational complex.   
While there is little evidence that Nova proteins are involved in translational 
control, a related protein, FMRP, is thought to have a primary role in post-synaptic 
regulation of translation.  FMR1 is a 38kb long gene composed of 17 exons, which are 
subject to alternative splicing and produce 20 predicted isoforms (4-5 protein bands are 
detected in various tissues) (Devys et al., 1993; Eichler et al., 1993; Khandjian et al., 
1995; Sittler et al., 1996; Verheij et al., 1993; Verheij et al., 1995).    FMRP has three 
conserved RNA-binding domains, two KH domains and one RGG box, and has been 
shown to exhibit a high affinity for polyG and polyU homoribopolymers in vitro 
(Adinolfi et al., 2003; Ashley et al., 1993; Denman and Sung, 2002; Dolzhanskaya et al., 
2003; Mazroui et al., 2003; Siomi et al., 1993)  In addition to the RNA-binding domains, 
FMRP also contains an N-terminal protein-protein interaction domain (NDF), a second 
protein-protein interaction domain (PPId), a phosphorylation domain (Phd), a nuclear 
localization signal (NLS) and a nuclear export signal (NES)  (Adinolfi et al., 2003; 
Ceman et al., 2003; Eberhart et al., 1996; Fridell et al., 1996; Siomi et al., 2002; Sittler et 
al., 1996). FMRP has two autosomal paralogs, FXR1P and FXR2P, which share >60% 
amino acid identity (Siomi et al., 1995; Zhang et al., 1995).  FMRP is normally expressed 
in most tissues at variable levels, although the highest expression is observed in brain and 
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testis (Abitbol et al., 1993; Devys et al., 1993; Hergersberg et al., 1995; Hinds et al., 
1993).  
Several laboratories have made efforts to identify the mRNA targets of FMRP.  
FMRP has been shown to negatively regulate the translation of several mRNAs, both in 
an in vitro rabbit reticulocyte lysate system and in vivo in cell culture (Laggerbauer et al., 
2001; Li et al., 2001b; Mazroui et al., 2002; Schaeffer et al., 2001).  Target RNA 
structural motifs have been identified for the RGG box domain (G-quartet RNA) and the 
second KH domain (kissing complex RNA) (Darnell et al., 2005a; Darnell et al., 2001; 
Darnell et al., 2005b).  FMRP has also been shown to bind its own mRNA (Ashley et al., 
1993; Brown et al., 1998; Ceman et al., 1999; Schaeffer et al., 2001). Fmr1 mRNA 
contains a G quartet FMRP binding site in the coding region which, when placed 50nt 
downstream of the 5’ cap structure of a luciferase reporter, confers translational 
repression in the presence of FMRP.  Of note, all attempts to reproduce a 3’UTR G 
quartet site have failed to confer translational repression (Schaeffer et al., 2001; JC 
Darnell, unpublished data).  Other target mRNAs for which there is some evidence of 
translational regulation by FMRP include elongation factor 1A (EF-1A) (Sung et al., 
2003), MAP1B (Brown et al., 2001; Darnell et al., 2001; Zalfa et al., 2003), and PSD-95 
(Todd et al., 2003).  Transcriptome-wide screening for FMRP target mRNAs has 
identified mRNAs that preferentially co-IP with FMRP in the presence of EDTA (Brown 
et al., 2001).  Some of these mRNAs also display an altered polyribosomal profile in cells 
from Fragile X patients. However, this study may have been biased toward identification 
of RGG box-binding mRNAs, since the co-immunoprecipitation buffer contained 30mM 
EDTA, which is known to disrupt ribosomes and KH2 binding to RNA (Darnell et al., 
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2005a).  In addition, mRNA targets differentially associated with polyribosomes in the 
presence or absence of FMRP were identified from lymphoblastoid cells, not brain.  
Other potential FMRP targets have been identified by antibody-positioned RNA 
amplification (Miyashiro et al., 2003) and in vitro RNA selection from transcribed 
sequences in brain (Chen et al., 2003).  However, little data at the protein level exist to 
confirm translational regulation of these mRNAs by FMRP.   
 
Methodologies to elucidate a role for FMRP and Nova proteins in translational control 
 In order to address potential functions for Nova-1, Nova-2 and/or FMRP in the 
regulation of translation in neurons, we have devised several approaches.  First, we have 
developed a method to purify and analyze polyribosomes from mouse brain and spinal 
cord lysates.  Subjecting these lysates to various treatments can provide more knowledge 
on whether these proteins are associated with polyribosomes or with other large 
complexes.  Second, mRNA isolated from purified polyribosomes of wild type and 
knockout mice can be interrogated by microarrays in order to screen for steady state 
changes in mRNA translation that are associated with these proteins.  Finally, we can use 
known RNA ligands to these KH domain-containing proteins to investigate whether 
binding to a particular RNA target has an impact on other protein-protein or protein-RNA 
interactions.  These experiments provide a foundation to address important aspects of 




CHAPTER II: MATERIALS AND METHODS 
 
Polyribosome analysis 
Polyribosomes from cortex or spinal cord were analyzed as follows. CD1 or FVB 
mice at various ages were killed by decapitation after anesthesia with chloroform. The 
brain or spinal cord was removed from the skull and placed in ice-cold buffer (10mM 
HEPES-KOH, pH 7.4, 150mM KCl, and 5 mM MgCl2) containing 100 µg/ml of 
cycloheximide. From this point on, the material was kept ice-cold or at 4°C throughout 
the preparation. From brain, the cerebral cortex was dissected free of cerebellum, 
brainstem, mesencephalon, diencephalon, basal ganglia, and much of the underlying 
white matter. For spinal cord, meninges were carefully removed.  Tissue was 
homogenized in 1 ml of homogenization buffer per cortex or per 4 spinal cords (except as 
noted) (homogenization buffer: 10 mM HEPES-KOH, pH 7.4, 150 mM KCl, 5 mM 
MgCl2, and 0.5 mM DTT) containing protease and RNase inhibitors (complete EDTA-
free from Roche and Rnasin from Promega). Tissues were homogenized with 12 strokes 
at 900 rpm in a motor-driven glass-Teflon homogenizer. The homogenized material was 
spun at 2000 x g, 10 min, and NP-40 was added to the supernatant (S1) to a final 
concentration of 0.3% or 1% v/v. After 5 min of incubation on ice, the material was spun 
at 20,000 x g for 10 min, and the supernatant (S2) was loaded onto 20-50% w/w linear 
density gradient of sucrose in 10 mM HEPES-KOH, pH 7.4, 150 mM KCl, 5 mM 
MgCl2, or 30 mM EDTA where indicated. In the indicated samples, EDTA was added to 
S2 to a final 30 mM concentration before loading on the gradient.  Material obtained 
from one cortex or one-half cortex was loaded onto each gradient. The gradients were 
centrifuged at 40,000 x g for 2 hr at 4°C in a Beckman Instruments SW 41 rotor. 
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Fractions of 0.5, 0.75, or 1 ml volume were collected with continuous monitoring at 254 
nm using an ISCO UA-6 UV detector. For the RNase experiments, before centrifugation, 
the S2 fraction was incubated with 1000 U/ml RNase T1 (Ambion) and 44 U/ml RNase 
A (United States Biochemical) for 10 min at room temperature. 
The same procedure was used for the analysis of polyribosomes extracted from 
cells in culture. A postmitochondrial extract was obtained by lysis of 1 x 107 N2a, 
IMR32, 293 or 293T cells (American Type Culture Collection) or primary cortical 
neurons from seven 10-cm-diameter dishes in 1 ml of the following buffer: 20 mM 
HEPES-KOH, pH 7.4, 10 mM KCl, 5 mM MgCl2, 0.3% NP-40, 0.5 mM dithiothreitol, 
40 U/ml Rnasin (Promega), and complete protease cocktail (Roche). The salt 
concentration was adjusted to 150 mM with 1 M KCl, and the lysate was spun 12,000 x 
g, 10 min at 4°C. The resulting supernatant was loaded on sucrose gradients as described 
above. 
The proteins contained in each fraction of the sucrose gradients were TCA-
precipitated and analyzed by Western blot. 
 
Western blotting 
Anti-FMRP (1C3, Chemicon; 2F5, hybridoma from J. Fallon), anti-S6 ribosomal 
protein (Cell Signaling Technology), anti-L7 ribosomal protein (GeneTex), anti-P0 
ribosomal protein (a kind gift from Dr. Tan, Scripps Institute; Biodesign International), 
and anti-poly(A) binding protein (PABP) (10E10; Immunoquest), anti-Nova (rabbit 
polyclonal and human patient sera), anti-Hu (human patient sera), anti-FXR1(830, gift of 
E. Khandjian and B. Bardoni), anti-FXR2 (1G2, Iowa Hybridoma Bank), anti-CYFIP1, 
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anti-CYFIP2, anti-NUFIP, anti-83FIP (all gifts of B. Bardoni), anti-hAgo1 and anti-
hAgo2 (gifts of T. Tuschl), anti-myoVa (Sigma), anti-puralpha (Abnova), anti-mStaufen 
(Chemicon), anti-YB1 (Abcam), anti-eIF4E (Santa Cruz), anti-EF1alpha (Novus), anti-
Sam68 (Upstate), anti-aPKCzeta (Sigma), and the appropriate HRP-conjugated secondary 
antibodies (Jackson Immunochemicals) were used for Western blotting.  Signal was 
detected by chemiluminescence. The membranes were exposed on Biomax MR film 
(Eastman Kodak) and to the digital camera of a Versadoc Imaging System (Bio-Rad). 
 
Pharmacological treatments of cells 
Cells in culture were treated with 0.35 mM cycloheximide (Sigma) for 10 min or 
with 1 mM puromycin (Sigma) for 3 hr before lysis, as described. Cycloheximide was 
dissolved in methanol, and puromycin was dissolved in water. 
 
In vitro transcription 
In vitro transcription of RNA for binding curves was performed with 13 µL of 
PCR-generated DNA template, 0.4 µM NTPs, 1 µL RNAsin (Promega), 40 µCi {alpha}-
32P-UTP, 1x transcription buffer (Stratagene), and 1 µL T7 RNA polymerase 
(Stratagene). RNA was treated with 3 units of RQ1 DNase for 45 min at 37°C and 
followed by gel purification on 8% denaturing polyacrylamide gels. 
 
Nitrocellulose filter binding assays 
Ten-thousand counts per minute (1-5 fmol) of internally labeled RNA (preheated 
to 75°C and cooled at room temperature for 5 min) was incubated with the indicated 
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concentrations of protein in a total volume of 50 µL in SBB, 10 min at room temperature. 
Binding solutions were passed through MF-membrane filters (0.45 HA, Millipore) and 
washed with 4 mL SBB. Filters were air dried and counted in 5-mL ReadiSafe scintillant. 
Data were plotted as percentage of total RNA bound versus log of the protein 
concentration and Kd's determined using Kaleidograph software (Synergy Software). 
 
RNA treatment of polyribosome preparations 
In vitro transcribed RNAs were prepared as described above, incubated in 100 µL 
of 1x SBB for 10 min at 75°C, then incubated for 15 min at room temperature. The 
supernatant (S1) from the homogenized material was collected and adjusted to 1% NP-
40, v/v. Two microliters of rRNasin, and 100 µL of in vitro transcribed RNA (or yeast 
tRNA, Roche) in 1x SBB were added to 1.1 mL of S1 and mixed by inversion. After 
incubation for 15 min at room temperature, S1 lysate was spun at 20,000 x g for 10 min 
at 4°C and the supernatant (S2) was loaded onto sucrose gradients as described above. 
 
Immunoprecipitation 
A post-mitochondrial supernatant (S2) from cerebral cortex was prepared as for 
polyribosome analysis and pre-cleared with 50µl protein A-sepharose (Sigma) for 30min 
at 4°C. Mixed monoclonal anti-FMRP IP matrix was prepared as follows:  120µl Protein 
A-sepharose was incubated with 12µl rabbit anti-mouse Fcgamma (2.4mg/ml, Jackson 
Immunochemicals) for 30 min. at room temperature, then washed three times with 0.1M 
NaPO4 buffer (pH 8.0) before incubation with 8µl 7G1-1 and 25µl 2F5 monoclonal 
antibodies overnight at 4°C.  Final IP matrix was washed three times with 0.1M NaPO4 
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buffer before addition to pre-cleared supernatant.  Immunoprecipitations were performed 
at 4°C for 2 hours, after which they were washed twice with brain lysis buffer lacking 
NP40.   
 
Microarray analysis 
Total cytoplasmic or polyribosomal RNA was isolated with TRIzol LS (Invitrogen) 
extraction followed by RNeasy (Qiagen) purification with DNase treatment on column.  
Ten µg of RNA was used as input for cRNA generation according to Affymetrix 
guidelines.  Biotin-labeled, fragmented cRNA was hybridized to either MGU74v2 ABC 
or MG430 2.0 GeneChips (Affymetrix).  Data analysis was accomplished as described in 




All lentiviral constructs and packaging reagents were obtained from D. Trono (Geneva, 
Switzerland).  Packaging plasmids psPAX2 (15µg) and pMD2.G (6µg) were introduced 
with 20µg pLVTt into 1x107 80% confluent 293T cells (ATCC) by calcium phosphate 
transfection (Invitrogen).  Virus-containing media was collected 48 hours after 
transfection and filtered through a 0.4µm membrane.  
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CHAPTER III: NEURONAL RNA-BINDING PROTEINS AND THEIR 
ASSOCIATION WITH POLYRIBOSOMES IN MOUSE BRAIN 
 
Introduction 
Translation of mRNA messages into functional proteins can be regulated in 
various ways by RNA-binding proteins in cells.  Once transcribed and spliced in the 
nucleus, mRNAs must be exported to the cytoplasm, transported to their subcellular 
destinations, protected from or encouraged to undergo translation, and degraded under 
the appropriate circumstances.  (Reviewed in (Moore, 2005)) However, these events in 
the lifetime of an mRNA do not exist in isolation, as supported by recent advances in the 
fields of transcription, pre-mRNA splicing, mRNA export, nonsense-mediated 
degradation (NMD) and translation.  Instead, they are coupled to the events that precede 
and follow.  Many proteins that bind a specific RNA at a given step in processing remain 
bound and function in downstream events.  It is through this network of regulatory 
mechanisms that additional layers of complexity are added to our genomic program for 
tissue-specific cellular function in a temporal and spatial fashion.   
Local control of translation is an important aspect of the regulation of gene 
expression, especially in neurons, which can extend processes and create synapses 
enormous distances from the cell body.  Although originally studied in developmental 
processes in Xenopus and Drosophila, mRNA targeting, localization, and translation have 
become a key aspects of the current theory of activity-dependent synaptic modification. 
(Richter and Lorenz, 2002; Steward and Schuman, 2003; Sutton and Schuman, 2005) In 
essence, for an mRNA to have a selective impact on a specific synapse, its transport must 
be correctly targeted to the translational area of that synapse. It follows that locally 
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translated messages should encode proteins that are in use at that synapse, modify other 
proteins at the synapse, or serve as messengers to send signals back to other parts of the 
neuron.  Finally, transport and/or translation of this mRNA must be regulated in a manner 
that can be altered by activity at that synapse.  
Many studies have shown that protein synthesis is required for long-lasting forms 
of behavioral and synaptic plasticity. (Govindarajan et al., 2006; Kang and Schuman, 
1996; Kelleher et al., 2004a; Mayford et al., 1996; Nguyen and Kandel, 1996)  Evidence 
for this hypothesis to date includes: localization of polyribosomes and associated 
membranous cisternae to sub-synaptic sites in dendrites, assessments of the mRNA 
complement of dendritic processes, protein synthesis in isolated synaptosomal 
preparations, translation of an mRNA construct transfected into an isolated dendrite, and 
studies of polyadenylation-induced translation of the αCaMKII mRNA in synaptosome 
preparations after NMDA receptor activation. (Crino and Eberwine, 1996; Eberwine et 
al., 2001; Gardiol et al., 2001; Huang et al., 2002; Miyashiro et al., 1994; Steward and 
Levy, 1982) 
Analysis of the subcellular distribution of a given RNA-binding protein by 
gradient centrifugation may offer clues to its function in vivo.  In particular, if the protein 
in question cosediments with polyribosomes, it may be involved in the regulation of 
translation of its target mRNAs.  Three target antigens for paraneoplastic neurologic 
disease (PND), Hu (family members HuB, HuC and HuD), Nova (family members 
Nova1 and Nova2), and Trim9 are neuronal RNA-binding proteins that may function in 
this manner.  Fragile-X mental retardation protein (FMRP) is a related RNA-binding 
protein that is also implicated in neurologic disease.  We show that the while only 10-
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25% of cytoplasmic Nova proteins are bound to polyribosomes, the majority of FMRP 
and the neuronal Hu proteins are associated with actively translating polyribosomes in 
brain and neuronal cells in culture. 
 
Results 
Polyribosomal protein analysis by gradient centrifugation 
Velocity sedimentation of cytoplasmic components by centrifugation through a 
sucrose gradient allows subsequent fractionation and simultaneous measurement of 
absorbance at 254nm.  This method was first used in 1961 to work out the basic 
mechanisms of protein synthesis, describing complexes that included multiple ribosomes 
and messenger RNAs, and thereby generating a polyribosomal profile for a given cell 
population (Becker et al., 1963; Gierer, 1963; Marks et al., 1962; Penman et al., 1963; 
Rich et al., 1963; Risebrough et al., 1962; Scherrer et al., 1963; Slayter et al., 1963; 
Spyrides and Lipmann, 1962; Staehelin et al., 1963a; Staehelin et al., 1963b; Warner et 
al., 1963a; Warner and Knopf, 2002; Warner et al., 1963b; Wettstein et al., 1963).  The 
UV absorbance tracing of post-mitochondrial supernatant sedimented through a 
continuous 20-50% (w/w) sucrose gradient displays clearly distinguishable peaks for the 
40S and 60S subunits, 80S ribosomal monomer, and subsequent increases in the number 
of ribosomes associated with mRNA.  Protein analysis of polyribosome gradients by 
Western blotting is one tool to understand whether a given RNA-binding protein is 
associated with ribosome-loaded mRNAs; such an association may indicate a role for that 
protein in the regulation of mRNA translation.  For example, FMRP co-sediments with 
polyribosomes from tissue culture cells (Corbin et al., 1997; Khandjian et al., 1996).  
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There are data to show that FMRP can negatively regulate the translation of several 
mRNAs, both in an in vitro rabbit reticulocyte lysate system and in vivo in cell culture 
(Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002; Schaeffer et al., 2001) 
In our studies of neuronal RNA-binding proteins, we have developed a method to 
fractionate polyribosomes from mouse cerebral cortex in order to ascertain the 
polyribosomal distributions of these proteins.   Several RNA-binding PND antigens 
demonstrate partial polyribosomal association in vivo.  There are several commonly used 
assays to demonstrate true polyribosome association and distinguish it from co-migration 
on a sucrose gradient.  Treatment with EDTA, translational initiation inhibitors that allow 
run-off of translating ribosomes, or RNase result in disruption of the polyribosomal 
profile and a change in the sedimentation rate of ribosomal proteins.  If a protein is 
indeed associated with polyribosomes, its sedimentation rate should mirror that of 
ribosomal proteins under these conditions.  Since EDTA chelates the magnesium ions 
necessary for 80S ribosome formation and stabilization, an EDTA-treated lysate will 
produce a profile showing two large peaks for ribosomal subunits (often off-chart and 
merged into a single peak) but no peaks corresponding to 80S ribosomes or 
polyribosomal complexes.  A polyribosome-associated protein may be bound to actively 
translating or stalled complexes.  To distinguish between these types of polyribosomes, 
sodium fluoride (NaF) and sodium azide (NaN3) can be used to inhibit ribosome re-
initiation in a cell lysate, allowing previously bound ribosomes to run-off the mRNA and 
complete translation.  The resultant UV profiles are shown in Figure 3.1A.  Protein from 
each fraction of each gradient was precipitated with tricloroacetic acid and analyzed by 



















Figure 3.1 Polyribosomal profiles and protein distributions: comparison of 
treatment with EDTA or translation initiation inhibitors. (A) UV absorbance profiles 
at 254nm of mouse brain lysate treated as indicated and centrifuged through 20-50% 
sucrose gradients.  Western blots for ribosomal protein S6 (B), the neuronal Hu proteins 
(C), and Trim9 (D).  (CH: 100ug/ml cycloheximide; EDTA: 30mM 
ethylenediaminetetraacetic acid; NaF: 30mM sodium fluoride; NaN3: 20mM sodium 
azide) 
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ribosomal subunit throughout the gradients (Figure 3.1B).  49% of total S6 protein is 
found in fractions 12-20, which correspond to polyribosomal complexes with more than 
five ribosomes. A 25% shift in the distribution of S6 is seen with EDTA treatment.  
Smaller shifts (16%) are evident in the NaF- and NaN3- treated samples.  These data 
confirm that 30mM EDTA disrupts polyribosomes, and that ribosome re-initiation 
inhibitors do have an impact on the number of ribosomes per message under these 
conditions.  Despite the incomplete translational run-off achieved here, partial sensitivity 
to NaF and NaN3 is still informative for our analysis of polyribosomal proteins. 
 
HuB, HuC and HuD 
The neuronal ELAV-related RNA-binding proteins HuB, HuC and HuD were 
visualized using sera from a patient with anti-Hu PND.  Although the ubiquitously 
expressed family member HuR (HuA) has been shown to associate with polyribosomes in 
cell culture and other tissues (Sheflin et al., 2001), this association had not been 
demonstrated for the CNS-specific HuB, HuC and HuD proteins.  HuB and HuC have 
been shown to be important for neuronal development in both the CNS and PNS.  
(Akamatsu et al., 1999) The Hu proteins contain RRM-type RNA-binding domains.  HuR 
has been shown to increase the stability of its target mRNAs, as well as increasing the 
translation of these messages into protein.  (Antic and Keene, 1997; Antic and Keene, 
1998; Antic et al., 1999; Gallouzi et al., 2000; Levine et al., 1993)   Figure 3.1C shows 
that 52% of neuronal Hu proteins are associated with polyribosomes containing more 
than 5 ribosomes (fractions 12-20) in mouse cerebral cortex.  When treated with EDTA, 
Hu proteins shift to the upper region of the gradient, mirroring the dissociation of 
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ribosomes into subunits shown by ribosomal protein S6. Furthermore, when treated with 
NaF or NaN3 in a run-off translation assay, Hu proteins show a 30% shift from their 
control peak at fractions 12-16 to several peaks between fractions 3 and 10.  This 




 Another PND antigen, tripartite motif (RING, B-box and coiled-coil domains) 9, 
or Trim9, shows partial association with polyribosomes.  While the amount of Trim9 
peaks in fractions 3-9 in both control and EDTA-treated samples, there is 25% less signal 
in fractions 12-22 of the EDTA-treated sample (Figure 3.1D).  However, Trim9 does not 
seem to be associated with actively translating polyribosomes, since a shift is not seen in 
the NaF- and NaN3-treated samples.  It is possible that Trim9 could be associated with 
stalled polyribosomes or other large complexes that are magnesium dependent.   Trim9 
has been shown to bind RNA (W. Y. Park, unpublished data). In addition, recent work 
indicates that it binds microtubules and is localized to the synapse.  (Li et al., 2001a; 
Short and Cox, 2006) 
 
Onconeural ventral antigens Nova1 and Nova2 
 Nova1 and Nova2 are closely related target antigens of paraneoplastic opsoclonus 
myoclonus ataxia (POMA).  Both Nova proteins contain three KH-type RNA-binding 
domains, and have been shown to bind YCAY-rich sequences.  (Buckanovich et al., 
1993; Jensen et al., 2000a)  The roles of Nova1 and Nova2 in the regulation of alternative 
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splicing in neurons have been extensively documented by our laboratory (Dredge and 
Darnell, 2003; Jensen et al., 2000a; Ule et al., 2003; Ule et al., 2005b).  However, while 
RNA splicing is almost always a nuclear process, approximately 40-60% of Nova is 
present in the cytoplasm (J. Ule, doctoral thesis).  Since RNA-binding proteins are often 
involved in more than one processing event, it is a reasonable hypothesis that Nova could 
be involved in the translational regulation of target mRNAs.  To test this hypothesis, the 
polyribosomal distribution of both Nova1 and Nova2 was visualized using high-titer 
POMA patient sera.  Figure 3.2A shows that the majority of Nova is found in the first 
two (lightest) fractions of the gradient, likely in small protein-only or mRNP complexes. 
UV absorbance profiles were not obtained for this experiment since fractions were 
collected through a pinhole at the bottom of the gradient tube.  This technique prevents 
accidental contamination of the heaviest fractions by proteins present in other regions of 
the gradient.  For control purposes, unchelated and EDTA-treated gradients were assayed 
for a number of proteins, as shown in Figure 3.2A, including non-polyribosomal proteins 
gamma-tubulin, PTEN and MAPK. In order to better quantify the percentage of cytosolic 
Nova that is associated with large magnesium-dependent complexes, Western blot 
chemiluminescence was quantified using the Versadoc Imaging System (Bio-Rad) for 
control and EDTA-treated polyribosome gradients.  Figure 3.2B illustrates that there is a 
sharp visual difference between the amount of Nova present in fractions 12-19 of control 
versus EDTA-treated polyribosome profiles, and 11.8% of cytosolic Nova shifts out of 
these fractions per gradient (one brain).  Conversely, 22.4% of total Nova signal is shifted 
to fractions 4-11 of the EDTA-treated gradient.  A repetition of this experiment yields an 




















Figure 3.2 10-25% of non-nuclear Nova proteins associate with polyribosomes in 
mouse cerebral cortex. (A) Western blots of polyribosomal distributions in the absence   
(-), or presence of EDTA (E) for Nova-1 and Nova-2 proteins (Nova), ribosomal protein 
S6 (rpS6), gamma-tubulin, PTEN and MAPK. (B) Western blots for Nova in (A) 
quantitated by fraction as a percentage of total Nova present in the post-mitochondrial 
supernatant.  
 






















































shown).  Thus, we can estimate that approximately 10-25% of brain cytosolic Nova is 
associated with large complexes in a magnesium-dependent manner that may in fact 
contain polyribosomes. 
 
Fragile-X Mental Retardation Protein 
Converging lines of evidence support a role for FMRP in translational control.  
FMRP is found associated with polyribosomes in various non-neuronal cell lines. (Corbin 
et al., 1997; Eberhart et al., 1996; Feng et al., 1997a; Khandjian et al., 1996)  In addition, 
the abundance of a set of mRNAs in the polyribosomal fraction is altered in human cell 
lines derived from Fragile X syndrome patients. (Brown et al., 2001) The Drosophila 
ortholog of FMRP, dFXR, has been shown to repress the expression of futsch at the 
translational level. (Zhang et al., 2001)  Finally, the ability of FMRP to act as a 
translational repressor of reporter constructs has been demonstrated in vitro and in 
transfected cells. (Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002)  It has 
been suggested that the loss of proper regulation of translation of FMRP target mRNAs 
underlies the morphological and functional abnormalities observed at some synapses of 
Fmr1-null mice. (Huber et al., 2002; O'Donnell and Warren, 2002)   
These observations introduce the question of whether they are relevant to FMRP 
function in the mammalian brain.  Technical difficulties in sedimentation studies using 
CNS tissue have, until recently, prevented researchers from being able to definitively 
show that FMRP is present on polyribosomes from brain. The most promising evidence 
showed that FMRP may co-sediment with polyribosomes in synaptosomal preparations 
from rat cortex, however, this data included neither an RNA absorbance profile nor 
 30 
sufficient biochemical controls for synaptosomal preparation purity (Feng et al., 1997b). 
In addition, a recent study reported that FMRP is in fact not associated with 
polyribosomes in brain extracts, but rather that it cosediments with the 80S ribosome and 
with heterogeneous complexes of smaller size. (Zalfa et al., 2003)   
We devoted a significant effort to improving existing methodologies for the 
purification of polyribosomes from mouse brain.  The essential differences in our 
technique are the dissection and removal of underlying white matter tracts from the 
cerebral cortex, and the use of 0.3% to 1% NP40 as a detergent instead of sodium 
deoxycholate.  Our method of polyribosome fractionation allows us to demonstrate that, 
indeed, FMRP is present on polyribosomes in brain in both juvenile (postnatal day 9, 
Figure 3.3A) and adult (5 months old, Figure 3.3B) mice.  OD254 absorption profiles and 
Western blots are shown for polyribosome gradients treated with either 5mM magnesium 
chloride or 30mM EDTA.  EDTA treatment entirely disrupts polyribosomal complexes 
into the small and large ribosomal subunits, as shown by the shift in rpS6 distribution.  It 
also results in a significant and similar shift in FMRP distribution, from association with 
the largest polyribosomes to co-sedimentation with, or slightly larger than, the 60S 
ribosomal subunit.  To examine whether the cosedimentation of FMRP with 
polyribosomes in the brain was RNA-dependent, extracts were treated with RNases A 
and/or T1, and analyzed by gradient centrifugation. This treatment resulted in complete 
disruption of polyribosomes, as shown by the shift of ribosomal protein P0, and also 
shifted FMRP to the lighter fractions of the gradient (Figure 3.3C). (Stefani et al., 2004)  
In addition, when extracts are treated with both RNase and EDTA, there is a small 

















Figure 3.3  FMRP is associated with polyribosomes in mouse cerebral cortex. UV 
absorbance profiles and Western blots for FMRP and ribosomal protein S6 (rS6) of 
polyribosome fractionations from cerebral cortices of juvenile (postnatal day 9, A) and 
adult (five months of age, B) mice.  A comparison between control conditions (MgCl2) 
and EDTA treatment shows that both FMRP and polyribosomes (profiles, rS6) are 
disrupted by chelation of magnesium for both juvenile and adult mice. (C) Treatment of 
juvenile (postnatal day 9) mouse cortical lysate with RNase A also causes FMRP and 
ribosomal protein P0 (P0) to shift into the upper fractions of the gradient.  (D) Treatment 
with both RNase A and EDTA (bottom panel) results in a supershift of EDTA-released 
FMRP complexes. Western blots for FMRP of polyribosome gradients from mouse 
cortical lysate with the indicated treatments. 












FMRP may exist in complexes of multiple sizes, which are differentially dependent on 
both magnesium and RNA.  These results are in agreement with previous observations in 
non-neuronal cell lines.  (Ceman et al., 2003; Eberhart et al., 1996)  
One variable used in previous polyribosome profiles from brain has been the 
presence or absence of ionic detergent such as deoxycholate.  (Bagni et al., 2000; Zalfa et 
al., 2003)  To rule out the possibility that the observed sedimentation pattern of FMRP 
might relate to the presence or absence of detergents, we analyzed gradients of brain  
extracts prepared in the presence of deoxycholate, Nonidet P-40, or in the absence of any 
detergent. After elimination of the insoluble material with a 20,000 x g centrifugation 
step, we obtained clearly discernible polyribosome peaks in sucrose gradients (Figure 
3.4A). In agreement with our previous results, FMRP cosediments with polyribosomes in 
this preparation, eliminating the possibility of technical artifacts caused by the presence 
of detergents in the extract. Conversely, we find that FMRP association with 
polyribosomes is completely disrupted by the presence of deoxycholate (Figure 3.4B). 
(Stefani et al., 2004)  These results demonstrate that FMRP is associated with 
polyribosomes in the brain. Khandjian and colleagues have reported similar findings on 
the impact of deoxycholate on FMRP distribution.  (Khandjian et al., 2004) 
The molecular mechanism through which FMRP might modulate the expression 
of its target mRNAs is unknown. Even tissue-culture studies have failed to convincingly 
show whether FMRP associates with actively translating polyribosomes or with 




















Figure 3.4 FMRP associates with polyribosomes in the absence of detergent.  Post-
mitochondrial supernatants from juvenile mouse cortices were prepared without detergent 
(A) and subjected to control (left panel) and EDTA (right panel) treatments, or in the 
presence of 1% Nonidet P40 (NP40) (B, left panel) or NP40 plus 0.5% sodium 
deoxycholate (DOC, right panel). Western blots of polyribosome gradient fractions are 
shown for FMRP and the ribosomal proteins S6 (rS6) and L7. 
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(RNPs).  It has been suggested that the phosphorylation state of FMRP may regulate 
whether it is associated with active or stalled polyribosomes.  (Ceman et al., 2003) 
In tissue-culture studies, the FMRP-polyribosome association has been disrupted 
by treatment with pleotropic inhibitors of translation reinitiation such as sodium fluoride 
and sodium azide (Ceman et al., 2003; Feng et al., 1997a),  but it is unknown whether the 
FMRP-polyribosome association can be disrupted with these agents in a cytoplasmic 
lysate from mouse cerebral cortex. Figure 3.5 shows the distribution of FMRP in control, 
EDTA-treated and translation re-initiation-inhibited conditions.  These data demonstrate 
that, when ribosomes are allowed to undergo run-off translation, 14% of polyribosomal 
FMRP shifts from fractions 12-21 into fractions 5-10. Further evidence for the 
association of FMRP with actively translating polyribosomes is shown in Figure 3.6. 
(Stefani et al., 2004)  To assess whether FMRP is associated with actively translating 
polyribosomes in cells of neuronal lineage, we treated Neuro-2a cells, a murine 
neuroblastoma cell line, with the translational inhibitor puromycin. Puromycin is an 
analog of amino-acyl transfer RNA that binds to the acceptor site of the ribosome, 
blocking elongation and causing premature release of the growing polypeptide chain. 
(Davis et al., 1974)  Therefore, the drug specifically targets actively translating 
polyribosomes.  We attempted to assay FMRP sensitivity to puromycin treatment in vivo 
by injecting puromycin into the intraperitoneal space of mice.  We were not able to obtain 
usable polyribosome gradients from the brains of these mice due to the lipid insolubility 
of puromycin.  As a relatively hydrophilic molecule, puromycin has difficulty crossing 
the blood-brain barrier. We were unable to achieve sufficient puromycin concentrations 
in the brain before the mice died due to systemic toxicity (data not shown.)  For these  
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Figure 3.5 FMRP cosediments with translating polyribosomes in mouse cortex.  
Western blots for FMRP from polyribosome gradient fractions in Figure 3.1 show that 
65% of FMRP is bound to polyribosomal complexes containing at least 5 ribosomes (top 
panel, fractions 12-20.  14% of this population of FMRP shifts under run-off conditions 
when translation initiation is inhibited by NaF or NaN3. 
 
 
reasons we have used a neuroblastoma cell line (Neuro2a) to test whether FMRP is bound 
to actively translating polyribosomes. 
FMRP cosediments with the larger polyribosomes in Neuro-2A cells treated with 
cycloheximide (Figure 3.6 top panel), as observed in the brain. After treatment of Neuro-
2A cells with 1mM puromycin for 3 hr, virtually all polyribosomes containing multiple 
(i.e., >4-6) ribosomes were fully disrupted, whereas the peak corresponding to the 80S 
ribosome monomer was markedly increased, as judged by the OD254 profile and the 
Western blot for ribosomal protein S6 (middle panel). Under these conditions, the 
sedimentation of FMRP shifts from fractions harboring large polyribosomes (more than 
six ribosomes) to less dense fractions. These FMRP-containing fractions present after 
puromycin treatment correspond either to non-translating monosome-size particles or to 
residual polyribosomes containing 2-4 ribosomes bound to mRNA.  Ribosomal protein 
S6 and Poly-A Binding Protein (PABP) shift to smaller fractions, mostly corresponding 



















Figure 3.6 FMRP associates with functional polyribosomes in neuronal cells.  Neuro-
2A cells treated with 100ug/ml cycloheximide (top), puromycin (middle) or 30mM 
EDTA and analyzed by sucrose gradient centrifugation.  Western blots are shown for 




demonstrate that FMRP is associated with functional polyribosomes in neuronal cells. 
(Stefani et al., 2004)   
 
Discussion 
We have optimized a reliable procedure for the analysis of polyribosomes from 
differentiated neural tissues, based on the careful dissection of cerebral cortex with 
removal of underlying white matter, followed by homogenization and lysis in mild 
conditions that preserve the interaction between various neuronal RNA-binding proteins 
and polyribosomes.  Data from these experiments demonstrate that neuronal proteins can 
exhibit varying degrees of polyribosomal association when analyzed by gradient 
centrifugation. Here we have looked at several proteins identified as target antigens for  
autoimmune responses initiated by the ectopic expression of these antigens in somatic 
cancer cells.  The results of these paraneoplastic autoimmune activations are neurologic 
syndromes whose constellation of characteristics can inform studies on the normal 
function of these proteins in neurons.  Trim9, identified as a target antigen of sera from a 
patient with paraneoplastic cerebellar symptoms (W. Y. Park, unpublished results), is 
partially located in heavy gradient fractions in a magnesium-dependent manner.  This 
association is resistant to treatment with translation reinitiation inhibitors, suggesting that 
Trim9 may be a component of a large complex that may include stalled polyribosomes.   
The Hu antigens, first described as targets of paraneoplastic subacute sensory neuropathy, 
encephalomyelopathy, and/or cerebellar dysfunction, are entirely associated with actively 
translating ribosomal complexes when present in the post-mitochondrial supernatant. 
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Approximately 15-20% of non-nuclear paraneoplastic opsoclonus-myoclonus ataxia 
(POMA) targets Nova1 and Nova2 are associated with polyribosomes in cerebral cortex.   
Although not a known target antigen for a paraneoplastic neurologic disorder, 
FMRP is related to Nova by means of their KH-type RNA-binding domains.  FMRP is 
widely expressed, with highest expression observed in brain and testis. (Abitbol et al., 
1993; Devys et al., 1993)  Despite the essentially ubiquitous distribution, the human 
syndrome caused by the absence of FMRP is most notably characterized by cognitive 
impairments. (O'Donnell and Warren, 2002)  Therefore, a detailed understanding of 
FMRP biology in the cerebral cortex is of great interest.  In addition, the clinical and 
biochemical data from Fragile-X patients suggest that a defect in mRNA processing may 
be a critical component of this syndrome.  We provide definitive evidence that FMRP is 
associated with polyribosomes in mammalian brain.  We reproducibly observed EDTA 
and RNase-sensitive association of FMRP with polyribosomes in extracts from cerebral 
cortex from young and adult animals.  Furthermore, we demonstrate that the complexes 
formed by FMRP with polyribosomes are translationally active in neuronal cells, because 
treatment with puromycin, sodium fluoride or sodium azide sufficient for disruption of 
polyribosomes decreases the rate of sedimentation of FMRP.  Association of FMRP with 
polyribosomes has been described in non-neuronal cell lines, but contradictory reports 
exist in the literature about the existence of such interaction in neural tissues. One 
previous report has suggested a possible association of FMRP with polyribosomes in 
neural tissue. (Feng et al., 1997a)  However, the evidence presented was not conclusive, 
in part because the absence of an absorbance profile makes the integrity and purity of the 
polyribosomes difficult to assess. In contrast, a recent report suggests that FMRP is not 
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associated with polyribosomes specifically in mouse brain, but instead cosediments with 
RNPs smaller than a single ribosome, (Zalfa et al., 2003)  The results presented in this 
study definitively demonstrate that FMRP cosediments with polyribosomes purified from 
cerebral cortex. The purity of the polyribosomes from cortex is comparable to 
preparations from cultured cells, as judged by absorbance profiles. 
Although the observed migration of FMRP on sucrose gradients and its sensitivity 
to EDTA and RNase are highly suggestive of an interaction between FMRP and 
translating polyribosomes, other interpretations cannot be ruled out a priori. Krichevsky 
and Kosik (Krichevsky and Kosik, 2001) have reported evidence for large molecular 
weight RNP granules in neurons. However, these data were obtained from primary 
neuronal cultures, and no such granules were seen in cells grown for 3 d in vitro (only 
after 7 d in vitro), suggesting a phenomenon closely related to culture conditions.  In our 
work, we see no evidence for such RNP granules on OD254 profiles of either young or 
adult mouse brain. In other studies, FMRP has been reported in large cytoplasmic 
complexes similar to stress granules in tissue culture after various treatments (Mazroui et 
al., 2002).  Again, we have not observed a measurable amount of FMRP in such 
complexes in untreated mouse brain. 
The association of FMRP with actively translating polyribosomes suggests that 
the protein may itself play a role in translational regulation. Previous studies have 
suggested that FMRP may promote mRNA translation. (Brown et al., 2001; Miyashiro et 
al., 2003; Todd et al., 2003)  Although in principle an association with actively 
translating polyribosomes might be consistent with a positive role on translation, a 
number of reports also suggest that FMRP may inhibit the translation of its target RNAs. 
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(Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002; Zhang et al., 2001) 
Interestingly, whereas puromycin clearly disrupts large FMRP-polyribosome complexes, 
FMRP still cosediments with the largest remaining polyribosomes containing three to 
four ribosomes rather than with the much more prominent peak of monomeric ribosomes 
(Figure 3.6). The less than complete shift of FMRP may be consistent with relative 
translational inhibition of some FMRP-associated transcripts. Alternatively, since FMRP 
is generally associated with larger polyribosomal complexes (compared to the 
distribution of ribosomal proteins, see Figures 3.3-3.6), its continued association with the 
largest remaining complexes may simply reflect incomplete treatment with puromycin, 
leaving a percentage of translating ribosomes intact.  A third possibility is that FMRP is 
bound to mRNAs that are longer than average, and can therefore carry a greater number 
of ribosomes.  Finally, FMRP binding may inhibit the rate of translation elongation, 
rather than initiation.  This causes the number of ribosomes on a transcript to increase, 
since the ribosomes are packed more closely together.  The association of FMRP with 
"stalled" polyribosomes has been shown previously to correlate with phosphorylation in 
non-neuronal cells treated with sodium azide. (Ceman et al., 2003)  Although unusual, 
examples of translational repression of mRNAs associated with polyribosomes have been 
reported.  Hac1 mRNA expression in yeast is regulated on translationally stalled 
polyribosomes by means of an RNA-RNA interaction between the 5’ UTR and a retained 
intron in the 3’ region of the message. (Chapman and Walter, 1997; Ruegsegger et al., 
2001)  Translationally suppressed nanos mRNA is associated with puromycin-sensitive 
polyribosomes in Drosophila, and is subject to translational runoff in vitro. (Clark et al., 
2000)  Moreover, it has been reported that lin-14 and lin-28 mRNAs, whose translation is 
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blocked by miRNA lin-4, are nonetheless found in the polyribosomal fraction. 
(Krichevsky and Kosik, 2001; Olsen and Ambros, 1999; Seggerson et al., 2002) Our 
puromycin results suggest that translation is occurring on FMRP-bound mRNAs; 
however, taken together, all of our data is consistent with a slow elongation rate.  By 
modulating the efficiency of translation of mRNAs that are fully engaged in 
polyribosomal complexes, FMRP might be suitable to mediate particularly rapid and 
reversible regulatory events, consistent with its proposed role in the regulation of protein 
synthesis-dependent synaptic plasticity. (Huber et al., 2002)  
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Identification of affected mRNA targets is critical to an investigation of the role 
of an RNA-binding protein in translational regulation.  While target mRNAs have been 
identified by co-immunoprecipitation and/or bioinformatics screen for a known binding 
sequence (Brown et al., 2001; Darnell et al., 2001), one can also look at the general 
contribution of an RNA-binding protein on the translational status of expressed mRNAs.  
As for the transcriptional state of a tissue, microarrays can be used to examine whether 
the absence of an RNA-binding protein changes the mRNAs engaged by multiple 
ribosomes.  This scheme for high-throughput expression screening based on mRNA 
translation states was first employed by Zong et al to compare translational profiles of 
resting and mitogenically-activated fibroblasts (Zong et al., 1999).   Briefly, mRNAs 
isolated from polyribosome fractions corresponding either to association with less than 
two or to association with two or more ribosomes were used to interrogate cDNA arrays.  
Polyribosomal profile patterns of mRNAs were compared between resting and activated 
cells.  A number of groups have used similar methods to assay the mRNA content of 
polyribosomes purified from conditions including poliovirus-infected HeLa cells 
(Johannes et al., 1999), human Fragile X lymphoblastoid cell lines (Brown et al., 2001), 
rapamycin-treated T cells (Grolleau et al., 2002), rapidly growing and rapamycin-treated 
Saccharomyces cerevisiae (Arava et al., 2003; Preiss et al., 2003), renal carcinoma cells 
expressing von Hippel-Lindau tumor suppressor protein (Galban et al., 2003), mouse 
glial progenitor cells with activation of the Ras and/or Akt signaling pathways (Holland 
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et al., 2004; Rajasekhar and Holland, 2004), cultured embryonic rat cortical neurons 
treated with BDNF +/- rapamycin (Schratt et al., 2004), Arabidopsis thaliana leaves 
under normal conditions and mild dehydration stress (Kawaguchi and Bailey-Serres, 
2005), and prepuberal and adult mouse testis extracts (Iguchi et al., 2006).  We have 
combined our method for polyribosome preparation with knockout animals for two RNA-
binding proteins, Nova-1 and FMRP. 
The identification of mRNA targets of FMRP is a goal of many laboratories in the 
field.  FMRP has been shown to negatively regulate the translation of several mRNAs, 
both in an in vitro rabbit reticulocyte lysate system and in vivo in cell culture 
(Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002; Schaeffer et al., 2001). 
However, in our hands, these data seem to result from a global inhibitory effect of FMRP 
on translation, rather than specific inhibition of a target mRNA (JC Darnell, unpublished 
data.)  FMRP has been shown to bind its own mRNA through a G quartet motif (Ashley 
et al., 1993; Brown et al., 1998; Ceman et al., 1999; Schaeffer et al., 2001). Other target 
mRNAs for which there is some evidence of translational regulation by FMRP include 
elongation factor 1A (EF-1A) (Sung et al., 2003), MAP1B (Brown et al., 2001; Darnell et 
al., 2001; Zalfa et al., 2003), and PSD-95 (Todd et al., 2003).  Many possible targets of 
FMRP have been identified through a number of screening methods.  Using co-
immunoprecipitation of FMRP-RNA complexes from mouse brain followed by 
oligonucleotide microarray screening, 432 mRNAs were identified with the ability to 
preferentially co-IP with FMRP (Brown et al., 2001).  251 mRNAs differing in the 
polyribosomal fractions of human normal and fragile X lymphoblastoid cell lines were 
also identified by microarrays.  Of these, 136 were increased in fragile X polyribosomes 
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and 115 were decreased.  14 of the co-IP-identified mRNAs were present in the 
polyribosome-identified group.  A G quartet sequence was identified in 8 of these 
mRNAs.  MAP1B was present in both groups, and was shown to be increased in 
polyribosomes from fragile X cells. However, this study may have been biased toward 
identification of RGG box-binding mRNAs, since the co-immunoprecipitation buffer 
contained 30mM EDTA.  It is possible that mRNA targets bound in a magnesium 
dependent manner by the KH2 domain of FMRP have not been identified by this study.  
In addition, mRNA targets differentially associated with polyribosomes in the presence or 
absence of FMRP were identified from lymphoblastoid cells, not brain.  The 
lymphoblastoid cell lines used for these experiments were derived from 5 human subjects 
in each group, introducing more biological variation than is present in inbred mice.  
Finally, there is evidence that RNA-protein complexes can be falsely co-
immunoprecipitated when the two components have been expressed in separate cell lines, 
then lysed and pooled, suggesting that there may be a significant number of false 
positives in the co-IP data (Mili and Steitz, 2004).  Thus, screens for differentially 
polyribosome-associated mRNAs in the brain of the Fmr1 KO mouse may reveal further 
information.   
Antibody Positioned RNA Amplification (ARPA) has identified another set of 
possible FMRP targets from primary rat hippocampal neuronal cultures (Miyashiro et al., 
2003).  Of the 83 cDNA clones identified by this method, 25% contain G quartets, 
although it is not stated what percentage of all neuronal mRNAs contain G quartets using 
the sequence definition particular to this paper.  In vitro RNA selection from transcribed 
sequences in brain (cDNA-SELEX) was used to identify 57 cDNAs, of which 2 contain 
 45 
G quartets (Chen et al., 2003).  MAP1B was identified by this method and shown to have 
23% decreased expression in Fmr1 KO cerebellum.   Finally, total RNA from pooled 
whole brains from adult wild type and Fmr1 KO mice were used to probe a cDNA 
microarray (D'Agata et al., 2002).  73 genes were identified with greater than 2-fold 
differences between WT and KO signal.  However, real-time PCR validation did not 
support the magnitude of the differences observed on the array.  Others have indicated 
that there are few deviations from normal steady-state expression levels for most genes in 
fragile X patient cells or Fmr1 knockout mouse brain (Jin and Warren, 2003). 
While the role of FMRP in translational regulation is being extensively studied, 
that for the Nova proteins has not yet been considered.  Although Nova-1 and Nova-2 are 
present in the cytoplasm of neurons, and do bind some mRNA targets in exonic regions 
(Dredge et al., 2005; Ule et al., 2003; Ule et al., 2005b), no translational targets of either 
Nova protein have yet been validated. Like the related RNA-binding proteins hnRNP K 
and hnRNP E1/E2 (Ostareck-Lederer and Ostareck, 2004), the Nova proteins may have a 
significant role in translational regulation.  It is generally thought that mRNAs associated 
with polyribosomes are being actively translated.  Our lab has preliminary data to suggest 
that 11.8-22% of Nova may be associated with polyribosomes in the mouse CNS at 
approximately one month of age (Racca et al., submitted).  Thus, it is an open question 
whether Nova inhibits translation of mRNAs in Nova-associated mRNPs, or whether 
Nova may promote or inhibit translation by binding directly to polyribosomes. If Nova 
acts in a similar manner to that which has been suggested for hnRNP K (Ostareck-
Lederer and Ostareck, 2004), we expect to see an increase in association with 
polyribosomes of target mRNAs in Nova-1 null mouse spinal cord.  Or, we may see a 
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more complex set of data, with some mRNAs increased and others decreased in Nova-1 
knockout polyribosomal RNA, as has been seen for the lymphoblastoid cell lines from 
patients with Fragile X mental retardation syndrome (Brown et al., 2001). Thus both 




Nova-1 wild type versus knockout mouse spinal cord 
Nova RNA-binding proteins, Nova-1 and Nova-2, are target antigens of 
paraneoplastic opsoclonus-myoclonus ataxia (POMA), a neurodegenerative disorder of 
autoimmune etiology (reviewed in Darnell, 1996).  Nova-1 is expressed in the ventral 
spinal cord, brainstem, deep nuclei of the cerebellum, and midbrain (Buckanovich et al., 
1993).  Nova proteins contain three hnRNP K-homology (KH) domains with RNA-
binding activity.  Although the Nova proteins are predominantly nuclear, they are present 
in significant quantities in the cytoplasm and Nova-1 has been co-localized with GlyRα2 
mRNA in post-synaptic regions of the dendrite (Racca et al., submitted).  While there is 
evidence that Nova proteins act to influence alternative splicing in neurons (Jensen et al., 
2000a; Ule et al., 2003; Ule et al., 2005b), they may also have a role in the local 
regulation of protein synthesis in neurons.  Both Nova-1 and Nova-2 are associated with 
polyribosomes in mouse brain and spinal cord in a magnesium-dependent manner (See 
Figures 3.1-3).  For this reason we have used gradient density centrifugation, 
fractionation and microarray (Affymetrix MGU74v2ABC GeneChips) hybridization to 
identify mRNAs that have an altered distribution on polyribosomes in Nova-1 knockout 
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spinal cord from four day-old mice.  To control for transcriptional differences between 
Nova-1 knockout and wild type spinal cord we have also assayed total RNA from the 
same samples.  Three biological replicates of four pooled spinal cords each were used for 
each genotype.  A representative polyribosome profile and Western blots are shown in 
Figure 4.1. Signal values for each probeset were calculated using Microarray Suite 5.0 
(Affymetrix).  Further data analysis was accomplished using Genespring 5.0 (Silicon 
Genetics).  To analyze the differences between total mRNA and polyribosomal RNA 
populations, these signals were compared irrespective of Nova-1 genotype.  The 
probesets that exhibited a change between total RNA and polyribosomal RNA (p<0.001) 
are shown in Figure 4.2.  Of note, these probesets include mRNAs for 21 ribosomal 
proteins (Table 4.1) containing oligopyrimidine tracts (TOP) in their 5’UTR regions and 
known to be translationally repressed in post-mitotic cells (Meyuhas, 2000). mRNAs 





























Figure 4.1 Polyribosome Fractionation from Nova-1 wild type and knockout mouse 
spinal cord.  Four spinal cords from postnatal day 4 mice were used for each 20-50% 
sucrose gradient centrifugation.  A representative OD254 profile is shown in the top 
panel.  Positions of the ribosomal subunits and polyribosomes are indicated.  Gradients 
were fractionated and aliquots assayed for protein by Western blot.  Polyribosomal 
distributions of Nova-1 and Nova-2 proteins (anti-Nova) and ribosomal protein P0 (anti-
P0) are shown for wild type (WT) and Nova-1 knockout (KO) spinal cords.  Fractions 9-
11 (red box) from each gradient were pooled to isolate polyribosomal RNA. 

































Figure 4.2 mRNAs that differ between Total and Polyribosomal RNA, p≤0.001.  
Normalized intensities (log scale) of probeset signals were compared by t-test between 
total RNA and polyribosomal RNA, irrespective of genotype.  Probeset signals are 









































Table 4.1 Genes encoding ribosomal proteins are translationally repressed.  
*Indicates a TOP mRNA; mRNAs interrogated by multiple Affymetrix probesets are 
indicated in parentheses 
 
 
ribosomal protein S12 3.48E-05
ribosomal protein L13* 4.97E-05
ribosomal protein S26 4.97E-05
ribosomal protein L41 1.01E-04
acidic ribosomal phosphoprotein PO* 1.22E-04
ribosomal protein, large, P1 1.22E-04
ribosomal protein L27a (x2) 1.31E-04
ribosomal protein S28 (x2) 1.55E-04
ribosomal protein S8* 2.24E-04
ribosomal protein L28 2.57E-04
mitochondrial ribosomal protein L52 2.71E-04
ribosomal protein P23* 3.60E-04
ribosomal protein S2 3.60E-04
ribosomal protein L23a, 3.60E-04
ribosomal protein P40* 3.79E-04
ribosomal protein L30* 4.24E-04
ribosomal protein L27A 5.17E-04
ribosomal protein L21 5.55E-04
ribosomal protein L31 5.69E-04
ribosomal protein S17* 6.34E-04
ribosomal protein S11* 8.11E-04
mRNA p-value 
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Figure 4.3 shows a graphical representation of RNAs that showed a difference 
between wild type and Nova-1 knockout polyribosomes with p<0.05.  Signals for each 
gene on the polyribosomal chips were normalized to the corresponding signal from total 
RNA by genotype and sample, thus all signals equal one for both wild type and Nova-1 
knockout total RNA data points.  Table 4.2 lists the mRNAs that exhibit a greater than 
twofold difference between wild type and Nova-1 knockout polyribosomal RNA.  We 
were unable to confirm these data by real-time quantitative PCR and Western blotting for 
changes in steady state protein levels between Nova-1 wild type and knockout spinal 
cords (data not shown.)  Of note, Nova-2 is also expressed in mouse spinal cord, albeit in 
dorsal rather than ventral areas.  Since Nova-1 and Nova-2 have similar RNA binding 
specificities, slight changes in the polyribosomal distributions of a Nova target mRNA 
















Figure 4.3 Comparison of mRNAs sedimenting with wild type versus Nova-1 
knockout polyribosomes. Probeset signals are normalized to Total RNA signal for each 
gene by genotype, thus all probesets have a normalized intensity of 1 in KO Total and 
WT Total conditions.  KO Polyribosome compared to WT Polyribosomes by t-test, p≤ 
0.05. 




























Table 4.2. Nova1-dependent changes in polyribosomal mRNAs. mRNA targets 
increased or decreased in Nova-1 KO polyribosomes relative to wild type polyribosomes 
and normalized to total RNA signal for each gene and genotype.  Genes are boxed by 











Change selenium binding protein 2 9.92polynucleotide kinase 3'- phosphatase (PNKP) 5.87
VACM (vasopressin activated calcium mobilizing) 4.73
epithelial membrane protein 3 4.51
homeodomain interacting protein kinase 1 3.91
RIKEN cDNA 2300004H16 gene 3.89





putative membrane protein 2.76
chloride channel regulator Icln (pseudogene) 2.64
EST, Weakly similar to RIKEN cDNA 2510008H07 [Mus musculus] 2.43
similar to testis expressed sequence 27, clone IMAGE:4950648, mRNA 2.42
BALC (brain and acute leukemia, cytoplasmic) 2.40
RIKEN cDNA 4933426K21 gene 2.40
RIKEN cDNA 2510005D08 gene 2.36
Cluster Incl U62674: histone H2a.2-615 , and histone H3.2-615 genes 2.35
neural stem cell derived neuronal survival protein 2.30
RIKEN cDNA C330026P08 gene 2.29
clone IMAGE:4507459, mRNA, partial cds 2.27
ESTs 2.14
vw95f07.r1 Stratagene mouse skin cDNA clone IMAGE:1262725 5', mRNA 2.09
exostoses -like 1 2.08
RIKEN cDNA 5830417I10 gene 2.07
EST, Weakly similar to NED4_MOUSE NEDD-4 protein [M.musculus] 2.07
ESTs, Moderately similar to COTE_HUMAN COTE1 PROTEIN [H.sapiens] 2.02
ESTs 6.13
EST (transcription factor?) 5.29
Mouse CNK (connector enhancer of ksr) 4.79
RIKEN cDNA 4933439F18 gene 4.3
Damage-induced neuronal endopeptidase (DINE) 4.16
RIKEN cDNA 5830415F09 gene 4.01
cell division cycle 45 homolog -like 3.92
Rho GTPase activating protein 6 3.53
ESTs 3.42
RIKEN cDNA 1110038G02 gene 3.38
ESTs sim to JC5629 mullerian-inhibiting substance type II receptor 3.35
Janus kinase 3 3.19
endothelin converting enzyme 2 3.12
RIKEN cDNA 1810031K17 gene 3.07
expressed sequence AI448652 2.95
ESTs 2.63
Ngfi-A binding protein 1 (NAB1) 2.63
Helicase-like transcription factor 2.56
ADAMTS15 2.55





Fas-activated serine/threonine kinase 2.41
acid phosphatase 2, lysosomal 2.4
RIKEN cDNA 2010002L15 gene 2.36
expressed sequence AI315192 2.32
RIKEN cDNA 1110012J22 gene 2.3
ESTs 2.28
RIKEN cDNA 1110021E09 gene 2.26
neuronal PAS domain protein 1 (nPAS 1) 2.19
RIKEN cDNA 2410018G23 gene 2.19
phospholipase A2, group IID 2.19
ESTs 2.19
RIKEN cDNA 5830401B18 gene 2.18
similar to cleavage stimulation factor subunit 3 1.15
Structural protein of Rauscher oncovirus p10 2.05
DAP-1 2.04




More recently, our lab has identified and validated an extensive network of Nova-
1 and Nova-2 RNA targets through two novel methods, cross-linked immunoprecipitation 
(CLIP, (Ule et al., 2005a)) and a custom Affymetrix splicing microarray (Ule et al., 
2005b).  For 1143 validated Nova targets, 1480 unique Affymetrix probesets were 
identified on the MGU74v2ABC GeneChips.  While this list of validated Nova target 
RNAs does not overlap with those in Table 4.2, using this validated target list, the 
complements of Nova-1 wild type and knockout polyribosomal mRNAs were compared 
anew.  Figure 4.4 illustrates the mean signal values each gene in Nova-1 knockout and 
wild type polyribosomes for each of the three GeneChips (A, B, and C) for the 
MGU74v2 mouse genome set.   For each chip type, gene signals from polyribosomal and 
total RNA samples are shown for wild type and Nova-1 knockout (left panels), and after 
normalization to the corresponding signal from total RNA by genotype (right panel).  
These gene expression patterns are clustered by similarity. It is interesting to note that 
while the majority of these RNAs show a great change between polyribosomal and total 
RNA distributions, none show a wild type vs. Nova-1 knockout fold-change of 2.0 or 
greater using either normalization scheme (Figure 4.4).  Validation of possible 
translational targets of Nova-1 identified in Table 4.2 bears further investigation with 

























Figure 4.4.  Polyribosomal profiles of Nova CLIP and splicing target mRNAs. 
Validated RNA targets identified by CLIP or splicing microarray methods (Ule et al., 
2003; Ule et al., 2005b) were interrogated by MGU74v2 A, B, and C GeneChips (A, B, 
and C panels, respectively.)  Left panels show dendrograms of probeset signals 
normalized by the standard GCRMA algorithm.  Right panels show the same 
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Fmr1 wild type versus knockout cerebral cortex 
The identification of mRNA targets of FMRP is a goal of many laboratories in the 
field. Several laboratories have identified putative G-quartet-containing mRNA targets of 
FMRP.  Because additional KH2-binding mRNA targets may not have been identified by 
these studies, we have performed a microarray screen to identify mRNAs that are 
differentially associated with polyribosomes in the cerebral cortex of P7 Fmr1 null mice 
(KO) compared to their wild type littermates (WT).  To control for sex differences, only 
male mice were used.  Briefly, cytoplasmic lysates from cerebral cortices (two per 
gradient) were prepared in buffer containing 1% NP40 and 5mM MgCl2.  20% of total 
lysate was taken for total RNA.  The remaining sample was fractionated by gradient 
centrifugation on a 20-50% sucrose gradient.  Fractions were collected and 15% of each 
fraction analyzed by Western blot.  RNA was extracted from the remaining 85% of each 
fraction.  RNA from fractions 10-13, corresponding to association with 6 or more 
ribosomes, was pooled as polyribosomal RNA.  Both total and polyribosomal RNAs were 
labeled by standard methods and used to interrogate Affymetrix Mouse 430 2.0 
GeneChips.  Six biological replicates from each genotype were prepared (12 mice from 
each genotype, 24 microarrays encompassing four groups with six replicates each).  A 
representative profile and Western blots are shown in Figure 4.5.  Data was analyzed 
using the Robust Multi-Array Average (GCRMA) method (Irizarry et al., 2003), 
GeneTraffic (Iobion/Stratagene), and GeneSpring 7.3 (Agilent). Comparisons between 
WT and Fmr1 KO polyribosomal mRNA levels directly (Figure 4.6A), or after 
normalization of each probeset to its mean signal in Total RNA by genotype (Figure 



















Figure 4.5 Polyribosomal fractionation of wild type and FMRP KO mouse brain.  
Two cerebral cortices from postnatal day 7 mice were used for each 20-50% (w/w) 
gradient.  Fraction 1 corresponds to the 0% sucrose brain lysate loaded on top of the 20-
50% gradient.  Fraction 16 is the heaviest 0.75ml fraction from each 12ml gradient. A 
representative RNA absorbance profile is shown at top.  Western blots are shown for 
anti-FMRP (1C3, Chemicon) and ribosomal protein S6.  Fractions 10-13 (boxed) were 
pooled from each gradient for extraction of polyribosomal RNA. Signal for FMRP in the 
FMRP KO sample is due to 1C3 cross-reaction with FXR1. (+: positive control for 
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Notably, Fmr1 is the only gene with a signal difference of greater than 2-fold (3 
probesets show 6.4-fold, 4.1-fold, and 1.7-fold increases in WT polyribosomal RNA.)  
Genes with signal differences greater than 1.27 are listed in Figure 4.6C and Table 4.3 (of 
these, the highest fold change is a 1.42-fold decrease).  Of these 39 genes, only three are 
increased in KO polyribosomes, while 36 are decreased.  In addition, three genes, 
gelsolin, proteolipid protein (Plp), and tuberin-like protein 1 were exhibited similar 
changes in two probesets on the chips.  Of note, FMRP has previously been shown to 
bind Plp mRNA (Wang et al., 2004).  A comparison of total RNA from WT and KO 
animals (Figure 4.7) reveals decreases of 4.9-fold, 3.25-fold, and 1.45-fold for the three 
Fmr1 probesets in KO total RNA.  Again Fmr1 is the only gene with a fold change above 
2.  No genes show an increase greater than 1.27-fold in KO total RNA.  38 genes exhibit 
signal decreases between 1.27-fold and 1.8-fold in KO total RNA, and are listed in Table 
4.4.  Of these, receptor (calcitonin) activity modifying protein 2 (Ramp2) exhibits a 
greater than 1.27 fold decrease in 3 probesets, and calbindin 1 and cartilage link protein 1 
show decreases in 2 probesets each.  Calbindin 1 and RGS13 have been previously 




















Figure 4.6 Wild type versus FMRP knockout polyribosomal mRNAs. (A) Mean 
signals from wild type polyribosome chips are compared to signals from FMRP knockout 
polyribosome chips for all probesets interrogated (MG430 2.0 GeneChip).  Black lines 
indicate a two-fold change.  (B) Comparison as in (A), except mean polyribosomal 
signals have been normalized to total mRNA levels by genotype for each probeset.  (C) 
Probesets exhibiting a fold-change greater than 1.27 between wild type and knockout 







Vacuolar protein sorting 35 
Stearoyl-Coenzyme A desaturase 2 
Spectrin beta 2 
Adenomatosis polyposis coli 
NA 
L1 cell adhesion molecule 
Fmr1 
RIKEN cDNA 11100020L19 
RIKEN cDNA 17000298D6 
Proteolipid protein 
Fmr1 
Serologically defined colon cancer antigen 
33 
RIKEN cDNA 4833415N24 
Splicing factor 3b, subunit 2 
RIKEN cDNA 8430415B05 
Phosphofructokinase, platelet 
Retinoblastoma binding protein 1-like 1 
RIKEN cDNA 2810017B07 
Amyloid beta (A4) precursor-like protein 2 
RIKEN cDNA 4930438O05 
Creatine kinase, mitochondrial 1, ubiquitous 
Janus kinase 1 
RIKEN cDNA 9930028C20 
Solute carrier family 18, member 2 
Gelsolin 
Zinc finger protein 291 
RIKEN cDNA 2350035C23 
RIKEN cDNA 9630020E24 
Abelson helper integration site 
RIKEN cDNA 2810482G21 
Carboxypeptidase D 
Topoisomerase II beta 
Protein kinase C epsilon 
Proteolipid protein 




Tuberin-like protein 1 
Erythrocyte protein band 4.1-like 2 
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Figure 4.7 Wild type versus knockout total RNAs.  Mean signals from wild type and 
FMRP knockout total RNA chips are compared for all probesets. Black lines indicate a 
two-fold change. 





















To assess the quality of this microarray data, we can look at several positive 
controls incorporated into the experimental design.  The significant decrease in Fmr1 on 
all KO chips confirms the genotypes of the mice used and the ability of these arrays to 
detect a change of this magnitude.  The quality of the polyribosome preparations can be 
assessed by comparing polyribosomal RNA to total RNA for wild type mouse cortex.  
This comparison identifies 18 probesets that increase greater than 2-fold in polyribosomal 
RNA, and 878 probesets that decrease greater than two-fold (Figure 4.8), none of which 
show significant changes in FMRP knockout mouse brain.  Of the 878 probesets that 
decrease, at least 32 assay for ribosomal protein mRNAs and identify a minimum of 24 
different ribosomal proteins.  This is consistent with work showing that many mRNAs 
encoding ribosomal proteins also contain a 5’ terminal oligopyrimidine tract (TOP  





















Figure 4.8 mRNAs that differ between wild type polyribosome and wild type total 
with fold change ≥ 2.  GCRMA-normalized intensities of probeset signals were 
compared by t-test between WT total RNA and WT polyribosomal RNA (knockout 
groups were not included for this comparison.)  Probesets are grouped by signal pattern 
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mRNAs), and that such mRNAs are translationally repressed in non-dividing cells 
(Meyuhas, 2000). 
Recent work by Julie Zang has identified mRNAs that UV cross-link to FMRP in 
vivo. To look specifically at these FMRP target mRNAs, 1451 Affymetrix probesets were 
identified for 1254 FMRP CLIP tag sequences.  A direct comparison of WT and KO 
polyribosomal signals for these mRNAs is shown in Figure 4.9A.  None exhibit greater 
than two-fold differences between groups.  Likewise, none exhibit greater than two-fold 
difference between WT and KO total samples (Figure 4.9B). FMRP target mRNAs are 
grouped by polyribosomal profile pattern between WT and KO mice in Figure 4.9C.  To 
correct for transcriptional changes between WT and KO mice, these analyses were 
repeated after normalization of polyribosomal signals to total signals by genotype and 
probeset (Figures 4.9D,E).  Our polyribosomal pattern profile data does not indicate that 
there is an obvious, reproducible change in polyribosomal association of target mRNAs 
in the absence of FMRP.   
Given the lack of robust FMRP-dependent polyribosomal association of target 
mRNAs, together with the confirmation of expected results for Fmr1 and TOP mRNAs, 
we can hypothesize that perhaps the presence of FMRP shifts a target mRNA in a subtle 
fashion between polyribosome fractions (for example, a shift from 15 ribosomes to 8 
ribosomes).  Thus it may be worthwhile to use real-time PCR to compare the distribution 
of the identified mRNAs (from the polyribosomal RNA comparison between WT and 
KO) over all individual fractions of the polyribosomal gradients of WT and KO cortices, 
thereby confirming, for example, a decrease in polyribosome association by a 




















Figure 4.9 Polyribosomal distributions of FMRP CLIP target mRNAs. mRNAs that 
UV-crosslink with FMRP in vivo are interrogated by probesets on MG430 2.0 
GeneChips.  (A, B) Scatter plots of probeset signals compared between WT and FMRP 
KO polyribosomal (A), and total RNA (B), standard GCRMA normalization, black lines 
indicate two-fold change. (C) Dendrogram of probesets normalized by the standard 
GCRMA algorithm.  (D) Scatter plot of probeset signals for WT vs. KO polyribosomes 
normalized to respective total signals.  (E) Dendrogram of probesets: polyribosomal 
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further elucidate the mechanism of FMRP, since data from previous studies is 
inconsistent as to whether FMRP increases or decreases translation of target mRNAs 
(Brown et al., 2001; Chen et al., 2003; Darnell et al., 2001).  Confirmation of 
translational regulation at the protein level by Western blot remains a more definitive 
method of validation, but presents its own difficulties in achieving an adequate signal to 
noise ratio.  Other possible issues in this work include the influence of neurotransmitter 
stimulation for FMRP action, and/or FMRP function at a small subset of polyribosomes 
in the cerebral cortex. Only a handful of mRNA targets have validated FMRP-dependent 
changes in protein level (Chen et al., 2003; Hou et al., 2006; Lu et al., 2004; Miyashiro et 
al., 2003; Wang et al., 2004; Zhang et al., 2001).   
Since FMRP is consistently associated with the most rapidly sedimenting 
polyribosomes in neurons, these data present three possibilities for a role of FMRP in 
translational regulation. First, FMRP may be associated with population of RNAs that are 
particularly lengthy. This is not the case in this data set, since the mRNAs in Table 4.3 
average 2570nt in length, with a distribution of 626 – 5995nt. Second, FMRP may be 
associated with a population of mRNAs that are translated at a slower rate.  Finally, 
mRNAs associated with FMRP may be stalled in translation, with many ribosomes bound 
but little translation occurring.  
 
Discussion 
These data present a picture of the steady-state translational profiles of mRNAs in 
the central nervous systems of two mouse models of human disease.  What is most 
remarkable is the very lack of robust changes in polyribosomal associations of mRNA 
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targets of these disease-related RNA-binding proteins.  The expected number of false 
positive results exceeds the number of probesets with significant changes identified in 
each experiment.  For example, of the 36,000 probesets included on the MGU74v2 
GeneChips, 1,800 probesets are expected to show a false positive change between 
conditions at p<0.05 (without multiple testing correction.)  In the comparison between 
Nova-1 wild type and knockout polyribosomal RNA, using three biological replicates per 
condition, only 67 probesets show a fold change greater than 2 with p<0.05 (Table 4.2).  
Furthermore, these differences are not reproducible by real-time PCR in our hands.  
However, expected results for TOP mRNAs are seen with high significance (p<0.001, 
Figures 4.2, Table 4.1).  This contrast between a comparison by genotype (wild type 
versus knockout) and by fractionation (total RNA versus polyribosomal RNA) is even 
more striking when six biological replicates are used for each condition.  When FMRP 
wild type total RNA is compared to wild type polyribosomal RNA, 896 probesets are 
identified with a fold change greater than two.  Yet, when wild type mouse cortex is 
compared to FMRP knockout cortex for either total or polyribosomal mRNA populations, 
the only probesets showing a difference greater than two-fold hybridize to the Fmr1 
mRNA itself.  These data stand in stark contrast to the 426 mRNAs identified previously 
as increasing or decreasing greater than two-fold in fragile X lymphoblastoid cell lines 
(Brown et al., 2001). There are a number of reasons for this contrast.  Our experiments 
used inbred mouse cerebral cortices with six biological replicates per condition, 
compared to the five independently transformed lymphoblastoid cell lines from non-
genetically identical humans for each condition.  Furthermore, we were able to use later 
generation microarray technology and analytic software, which may further decrease the 
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statistical impact of outlier data points. Taken together, these data indicate that the 
steady-state transcriptional and translational profiles do not exhibit significant changes in 
the absence of Nova-1 or FMRP.   
Efforts to maximize the signal to noise ratio in polyribosomal profile pattern 
analysis by microarray are ongoing in our laboratory.  For the Nova proteins, double 
Nova-1 and Nova-2 knockout mouse brains show increased splicing affects for target 
RNAs (M. Ruggiu, J. Ule, H. Wang, and A. Mele, unpublished data.)  It is likely that any 
affect of Nova on polyribosomal association of target mRNAs will be amplified in double 
knockout mice.  
Similarly, two neuronal proteins closely related to FMRP, FXR1 and FXR2, may 
share redundant functions with FMRP.  A mouse model that eliminates the contributions 
of all three of these proteins in neurons would be an ideally suited for polyribosomal 
mRNA interrogation of microarrays.  Furthermore, recent evidence indicates that FMRP 
can contribute to activity-dependent, rapid fluctuations in protein levels in hippocampal 
neurons (Hou et al., 2006).  The magnitude of these DHPG-induced protein changes is at 
most a 50% change, as assayed by Western blot.  Thus, real changes in polyribosomal 
association that occur in response to activity in specific neurons are likely to be 
overwhelmed by the steady state levels of mRNA translation that exist in the unaffected 
neurons and glia in mouse cerebral cortex.  Other methods could include chemical or 
electrical stimulation of neuronal activity to increase the FMRP-dependent change in 
polyribosomal mRNAs.  A more rigorous dissection of polyribosomal profile patterns for 
FMRP target mRNAs under a variety of conditions including synaptic activity and/or 
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abrogation of redundant function of FMRP-related proteins may provide a foundation for 
future research evaluating the mechanism of translational regulation by FMRP. 
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CHAPTER V: KISSING COMPLEX RNA MEDIATES INTERACTION 
BETWEEN FMRP AND BRAIN POLYRIBOSOMES 
 
Introduction 
Fragile-X Mental Retardation Protein (FMRP), the product of the FMR1 gene, is 
characterized by a number of protein-protein interaction domains, and three RNA-
binding domains, specifically two tandem KH-type RNA-binding domains and a third 
RGG-type RNA-binding domain (RGG box). Although transcriptional silencing of 
FMR1 due to trinucleotide repeat expansion and hypermethylation is the most frequent 
cause of the disorder, patients expressing mutations or deletions within FMR1 have been 
described (Jin and Warren, 2003), emphasizing that loss of FMRP function leads to the 
Fragile-X syndrome. Given that the loss of FMRP activity leads to complex behavioral 
and cognitive deficits, understanding FMRP function has the potential to provide a link 
between molecular neurobiology and higher brain function. 
FMRP is believed to regulate mRNA translation in the brain, although the 
mechanism for this action, and the RNA targets of this regulation, are unknown.  We and 
others have demonstrated that FMRP is present on polyribosome fractions from both 
brain and tissue culture cells.  (Corbin et al., 1997; Feng et al., 1997a; Feng et al., 1997b; 
Khandjian et al., 1996; Khandjian et al., 2004; Stefani et al., 2004)  Additional data 
suggests that there may be a link between FMRP function and microRNA (miRNA) 
regulation of translation, since miRNAs are associated with polyribosomes (Bartel, 
2004), and FMRP co-purifies with components of the RNA-induced silencing complex 
(RISC) (Caudy et al., 2003; Caudy et al., 2002; Ishizuka et al., 2002; Jin et al., 2004). 
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Previous studies in cell lines have examined the requirement of various domains 
of FMRP for association with polyribosomes.  EBV-transformed lymphoblastoid cell 
lines from a patient with a missense mutation (I304N) in FMRP have been used to study 
the impact of this mutation on the association of FMRP with polyribosomes.  Located in 
KH2, the I304N mutation does not impair capture of FMRP via association with poly(A) 
RNA, so mRNA binding is still possible for this mutant.  However, association of FMRP 
with polyribosomes is abolished by I304N, and mRNPs containing I304N are abnormally 
small.  (Siomi et al., 1994) FXR2P, an FMRP ortholog and interacting protein, remains 
associated with polyribosomes in the presence of I304N FMRP. (Feng et al., 1997a)  
Transfections of FMRP deletion constructs into an FMRP-null cell line reveal that the 
protein-protein interaction (PPId), KH1 and KH2 domains are all required for association 
with polyribosomes. Point mutations in either KH1 (I241N) or KH2 (I304N) abrogate 
binding of FMRP to polyribosomes and show a diffuse cytoplasmic distribution.  In 
contrast, deletion of the RGG box results in a wild type distribution of FMRP on 
polyribosomes and punctate cytoplasmic distribution. (Darnell et al., 2005b)  
Interestingly PPId and KH1, but not KH2, are required for FMRP interaction with 
FXR1P, in an RNA-independent manner.  Finally, the RGG box seems to be required for 
incorporation of FMRP into temperature-sensitive stress granules in the cytoplasm of 
cells. (Mazroui et al., 2003)  In the phosphorylation domain (Phd) of FMRP, Ser499 can 
be phosphorylated by casein kinase II (CKII).  Phosphorylation of FMRP at this site has 
been shown to be associated with stalled polyribosomes in cell culture, while Ser499Ala 
FMRP is associated with actively translating polyribosomes.  Phosphorylation seems to 
have no effect on the magnesium- and RNA- dependence of FMRP association with 
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polyribosomes, and hasn’t shown an effect on FMRP binding to known targets in vivo 
(although an effect of phosphorylation on dFMR binding to ribohomopolymers has been 
demonstrated.) (Ceman et al., 2003; Siomi et al., 2002)  Thus it seems that the KH2 
and/or KH1 domains of FMRP, but not the RGG box, are required for association with 
actively translating polyribosomes. 
The finding that the I304N mutation can reduce FMRP binding to 
ribohomopolymers offers a clue to the function of the KH2 domain. (Siomi et al., 1994)  
Structure-studies of KH domains from analogous proteins indicate that the FMRP I304N 
mutation maps to the RNA binding pocket and is critical for stabilizing sequence-specific 
RNA-protein interactions.  (Lewis et al., 2000; Ramos et al., 2003b)  RNA selection with 
full-length FMRP has led to the identification of high-affinity FMRP RNA ligands that 
harbor a signature structural motif termed a G-quartet. (Brown et al., 2001; Darnell et al., 
2001)  G-quartets are stacked coplanar arrays of 4 guanine bases each, stabilized by 
cyclic Hoogsteen bonding between guanines.  Of the three RNA-binding domains in 
FMRP, G-quartet RNA binding maps to the RGG box. (Darnell et al., 2001)  Evaluation 
for G-quartets has been widely used to screen candidate FMRP RNA targets, identified 
through a variety of approaches, including bioinformatics, immunoprecipitation and 
DNA chip analysis, antibody-positioned RNA amplification, and biochemical 
approaches. (Brown et al., 2001; Darnell et al., 2001; Miyashiro et al., 2003; Schaeffer et 
al., 2001; Todd et al., 2003) Biochemical studies have suggested that FMRP may 
associate with specific mRNAs on polyribosomes; several mRNAs were found to have 
altered polyribosome distributions in lymphoblastoid cells obtained from Fragile X 
patient cells and to harbor G-quartet motifs. (Brown et al., 2001; Darnell et al., 2001)  
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Subsequent analysis of one of these targets, MAP1B, suggests that the Drosophila 
homolog of this protein (futsch) may be regulated at the translational level by the 
Drosophila FMRP homolog, dFMR. (Zhang et al., 2001) 
Subsequent RNA selection with the KH1 and KH2 domains of FMRP identified a 
loop-loop pseudoknot, or “kissing complex” motif as a high affinity ligand for KH2. 
(Darnell et al., 2005a)  The nature of the kissing complex structure, containing two stem-
loops that form a third stem and an additional inter-loop base pair, has prevented easy 
identification of endogenous kissing complex RNAs that may be regulated by FMRP. 
Detailed analysis of the FMRP KH domain-RNA interaction revealed that binding to the 
kissing complex is KH2-specific, and is abrogated by the I304N mutation. Binding is 
dependent in part on the RNA structure and on several specific nucleotides, as indicated 
by Mg+2-dependence, chemical modification, and mutational analysis. (Darnell et al., 
2005a) 
Identification of the kissing complex as a KH2 target allowed us to re-examine 
the nature of FMRP association with polyribosomes. We find that the association of 
FMRP with brain polyribosomes is entirely and specifically competed by kissing 
complex RNAs. These results suggest that mental retardation associated with the I304N 
mutation, and likely the Fragile-X syndrome more generally, may relate to a crucial role 
for RNAs harboring kissing complex motifs as targets or mediators of FMRP 




FMRP RNA-binding domains bind different high affinity RNA ligands   
We have tested the hypothesis that the RNA-binding ability of KH2 may mediate 
polyribosome association with a novel method that forces endogenous FMRP in mouse 
brain lysate to choose between binding a high affinity RNA ligand and binding its 
endogenous RNA targets, in a domain-specific manner.  Our lab has identified high 
affinity RNA target ligands through in vitro RNA selection (SELEX) of a pool of random 
96-mers for FMRP binding. (Darnell et al., 2005a; Darnell et al., 2001)  Two groups of 
target sequences have been identified. Those that bind preferentially to the RGG box of 
FMRP contain a G quartet structure that is required for binding (gqRNAs), and those that 
bind to KH2 exhibit a loop-loop pseudoknot “kissing complex” structure.  This binding is 
sequence- and structure- specific, as mutations in the RNAs and or protein domains can 
abrogate binding.  (For a thorough treatment, see details in (Darnell et al., 2005a; Darnell 
et al., 2001)).  Figure 5.1 shows the an experimentally derived structure for high affinity 
RNA ligands of the G-quartet type (sc1; Figure 5.1A; adapted from (Darnell et al., 2001)) 
an M-Fold predicted structure for an RNA of the kissing complex type (kc2; Figure 5.1B; 
(Zuker, 2003)).  A mutation that abrogates binding to FMRP is indicated for each.  A 
consensus structure from experimental data for kcRNA folding is shown in Figure 5.1C 
and illustrates the requirement for an inter-loop stem and a Watson-Crick base pair “kiss” 
















Figure 5.1 Experimental and predicted structures of FMRP RNA ligands. (A) 
Experimentally derived G-quartet RNA structure of sc1 RNA (Darnell et al., 2001), 
arrow indicates a mutation that abrogates binding to FMRP.  (B) Mfold-predicted 
structure of kc2 RNA folding (Zuker, 2003).  Green dots indicate nucleotides that form a 
stem between loops. Pink asterisks indicate the base-pair “kiss” between opposing sides 
of the loops.   The G23C mutation prevents this “kiss” and binding by FMRP.  (C) An 













kcRNA can shift FMRP off polyribosomes in brain lysate 
The first suggestion that FMRP might be involved in translational regulation was 
based on findings that it associated with polyribosomes in tissue culture cell lines, and 
that this association was abrogated by the I304N mutation.  We have used both kcRNAs 
and gqRNAs to compete with endogenous RNAs for FMRP binding as a tool to analyze 
the importance of KH2 and RGG RNA-binding domains on FMRP association with 
polyribosomes.   As an initial experiment, post-mitochondrial supernatant from postnatal 
day 9 mouse cerebral cortex was prepared using standard conditions for polyribosome 
analysis.  This lysate was incubated with either 500nM in vitro transcribed kc1 RNA or 
an equal volume of RNA folding buffer (1X SBB) for 15 minutes at room temperature.  
Samples were then loaded on 20-50% (w/w) sucrose gradients and analyzed using 
standard methods.  The resulting Western blots are shown in Figure 5.2.  While the 
distributions of ribosomal protein S6 (rpS6) and gamma tubulin remain consistent 
between samples, the distribution of FMRP changes dramatically in the sample treated 
with kc1 RNA.  While FMRP signal peaks in fractions 13-20 in the control sample, all 
FMRP in the kc1 RNA-treated gradient is located in fractions 3-6, a complete shift to the 
lighter area of the gradient.   Thus, it appears that in the presence of kcRNA, FMRP 
dissociates from a fast-sedimenting complex into a smaller particle.  Since kcRNA does 
not disrupt the distribution of the small ribosomal subunit (as shown by rpS6), and since 
FMRP has been shown to associate with actively translating polyribosomes (Stefani et 
al., 2004), it is a reasonable hypothesis that the presence of kcRNA results in the specific 
dissociation of FMRP from polyribosomes in brain lysate, leaving previously FMRP-













Figure 5.2 Kissing complex RNA competes FMRP off polyribosomes.  Extracts from 
mouse cerebral cortices were incubated with 500nM kc1 RNA (kc1) or an equal volume 
of buffer (-) before polyribosome gradient fractionation on 20-50% sucrose gradients. 
Western blots of gradient fractions are shown for FMRP (A), ribosomal protein S6 (B), 













































that the KH2 domain is required for FMRP cosedimentation with polyribosomes. 
(Darnell et al., 2005b; Mazroui et al., 2003) 
To look for a dose-dependent effect on competition of kcRNA with endogenous 
targets that mediate the FMRP:polyribosome complex, and to define the approximate 
affinity of this interaction, we tested increasing concentrations of kcRNA.  When brain 
polyribosomes were incubated with 3-500nM kc2 RNA, we observed a dramatic dose-
dependent shift in FMRP sedimentation from the polyribosomal fractions to light 
fractions corresponding to a size smaller than the 40S ribosomal subunit (Figure 5.3B). 
As seen with kc1 RNA, FMRP shifts from fractions 10-14 (of 16) to fractions 2-4 when 
in the presence of 500 nM kc2 RNA. The global polyribosomal profile was unchanged, as 
shown by UV absorbance tracings for 0nM and 500nM kc2 RNA (Figure 5.3A).  
Quantitation reveals that the half-maximal FMRP shift off polyribosomes occurred at an 
RNA concentration of approximately 100nM (Figure 5.3C), similar to the KD for FMRP 
binding kc2 RNA in vitro (~66nM).  The ability of kissing complex RNA ligands to 
compete endogenous FMRP off polyribosomes suggests that this ligand mimics the site 
FMRP uses to regulate translation in neurons. 
 
FMRP:polyribosomes are specifically dissociated by kcRNA 
To assess the specificity of these results, and to further probe the role of RGG 
box-mediated RNA binding in FMRP polyribosome association, the experiment was 
repeated with sc1 RNA, a G-quartet ligand (gqRNA) for the RGG box.  Sc1 RNA binds 
purified FMRP with an affinity of approximately 8nM in vitro. (Darnell et al., 2001)  As 
a critical control, we tested mut kc2, a point mutant in kc2 that destroys a critical base 
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Figure 5.3  Exogenous kc2 RNA dissociates FMRP from polyribosomes in a 
dose-dependent manner. (A) P8 mouse cerebral cortical extracts were separated 
by sucrose density gradient (20%-50%) centrifugation; positions of the 80S 
monosome and polyribosomes are indicated. Indicated amounts of kc2 RNA were 
added to brain lysates and incubated for 15 min at room temperature prior to 
centrifugation. A254 profile of sucrose density gradients for the lowest and 
highest kc2 RNA concentrations are shown; A254 profiles for all kc2 
concentrations were indistinguishable (data not shown). (B) Western blots of 
indicated fractions from sucrose density gradients incubated with the indicated 
kc2 concentration were probed with the FMRP monoclonal antibody 1C3. 
Fractions corresponding to 40S, 60S, and 80S ribosomal peaks are indicated. 
Ribosomal protein S6 was unshifted at all kc2 concentrations (data not shown). 
(C) Quantitation by chemiluminescence of the Western blot data in B (Versadoc 
imaging); the percentage of FMRP present in each fraction as a function of the 
total FMRP signal in that gradient is indicated. Inset shows a plot of the percent of 
FMRP shifted off the polyribosomes plotted against kc2 concentration 
(nanomolar). The half-maximal concentration of kc2 able to compete FMRP off 
of polyribosome fractions is ~100 nM kc2 RNA. 
 78 
 79 
pair in the loop-loop interaction (G23C, see Figure 5.1, (Darnell et al., 2005a)), and mut 
sc1, a point mutant in sc1 that destroys the G-quartet (G34C, (Darnell et al., 2001)).  In 
each case, the association of FMRP with polyribosomes was unaffected (Figure 5.4).  As 
an additional control, we evaluated sedimentation of the neuronal Hu RNA-binding 
proteins, since the nonneuronal Hu isoform is known to be polyribosome associated. 
(Gallouzi et al., 2000; Okano and Darnell, 1997) We found that the neuronal Hu proteins 
are polyribosome associated in mouse brain, but that neither kcRNA nor gqRNA was 
able to disrupt this association (Figure 5.4). These results demonstrate that kcRNA 
specifically disrupts FMRP polyribosome association. Taken together, these experiments 
suggest that the binding of KH2 to kissing complex RNA ligands may mediate 
polyribosomal association in the brain, while association of the RGG box with G-quartets 
is not required for stability of the complex. 
The ability of kcRNA to fold correctly and bind KH2 is dependent on the 
presence of a magnesium ion coordinated between the two loops of the pseudoknot.  As a 
result, KH2 is unable to bind kcRNA in the presence of EDTA. (Darnell et al., 2005a)  
However, the interaction between the RGG box and gqRNA is unaffected by EDTA.  
(Darnell et al., 2001)  To confirm that even an increased concentration of gqRNA is not 
able to change the sedimentation rate of polyribosome-associated FMRP complexes, 
brain lysate was incubated with 5µM sc1 RNA (Figure 5.5).  Although there is some 
variation between the FMRP distributions of 500nM sc1 and mut sc1, 5µM sc1 RNA and 
control samples, there is no consistent effect of gqRNA, even at a concentration 
approximately 500 times that of its in vitro affinity for FMRP.  To analyze whether 




















Figure 5.4 Kissing complex, but not G-quartet RNA, competes FMRP off 
polyribosomes. Western blot as in Figure 5.3 of sucrose density gradients in which 
indicated RNAs were used to compete FMRP polyribosomal association; mut kc2 
harbors a single point mutation in kc2 RNA, and mut sc1 harbors a single point mutation 
that destroys G-quartet formation and FMRP binding (indicated in Figure 5.1). Western 
blots were probed with antibodies to the indicated proteins, including FMRP, ribosomal 
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mRNPs that have been dissociated from polyribosomes (see Figure 3.4D), brain lysate 
was incubated with 500nM sc1 or mut sc1 RNA plus 30mM EDTA.  UV absorbance 
profiles for RNA+EDTA-treated samples do not differ from a profile of a sample treated 
with EDTA alone (Figure 5.5A).  Western blots for these gradients reveal that FMRP is 
located in fractions 2-7, as expected since EDTA disrupts polyribosomes. (See Chapter 3; 
(Stefani et al., 2004))  However, as shown in Figure 5.5B, there is no significant 
difference between the FMRP distributions for sc1 + EDTA and mut sc1 + EDTA. In 
addition, incubation of lysate with both kcRNA and gqRNA produces an FMRP 
distribution that is identical to that of treatment with kcRNA alone (Figure 5.4, bottom 
panel).  While these data suggest that gqRNA targets are not involved in regulating 
whether FMRP is associated with large complexes, this result does not rule out the 
possibility that FMRP mRNPs (that have been dissociated from polyribosomes by 
EDTA) contain G-quartet mRNAs.  This question warrants further investigation using 5-
25% sucrose gradients for a finer assessment of FMRP sedimentation rates under these 
conditions, and is being pursued by another PhD candidate in the lab. 
We also examined whether an irrelevant RNA could disrupt the 
FMRP:polyribosome interaction.  Nova proteins contain KH-type RNA-binding domains 
that bind in vitro selected RNAs harboring a stem-loop structure and a YCAY motif. 
“10021” RNA binds Nova KH domains with an affinity of ~500nM. (Jensen et al., 
2000b) Competition for KH-mediated RNA binding by 30uM 10021 RNA does not 
disrupt the interaction of Nova with large complexes (Figure 5.6A). Furthermore, 10021 




















Figure 5.5 sc1 RNA does not change FMRP distribution on polyribosomes or in 
EDTA-liberated mRNPs.  A254 profiles (A) and Western blots (B) for mouse cerebral 
cortex treated with sc1 RNA, mutant sc1 RNA and/or EDTA before sucrose 
centrifugation.  The in vitro binding affinity of the FMRP RGG box for sc1 is 
approximately 8nM (Darnell et al., 2001). 
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Figure 5.6 Sucrose gradient distributions of Nova-1, Nova-2 and FMRP are 
unaffected by the presence of 10021, an RNA ligand for the Nova KH domains.  
Western blots for Nova (A) and  FMRP (B) from TCA-precipitated sucrose gradient 
fractions analyzing mouse cerebral cortex lysate under treatment with exogenous 10021 
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RNA ligand that binds a KH domain of another RBP is not able to disrupt the interaction 
of FMRP with polyribosomes. 
 
BC1 RNA and tRNA do not compete for KH2 binding 
It has recently been reported that FMRP binding to BC1, a neuron-specific, 
dendritically localized nontranslatable RNA (Brosius and Tiedge, 2001), may play a role 
in modulating mRNA translation (Zalfa et al., 2003).  It has also been reported that 
FMRP binds to highly structured RNAs such as tRNA. (Gabus et al., 2004)  We tested 
whether an excess of BC1 RNA or tRNA was able to compete FMRP off polyribosomes 
(Figure 5.7). Addition of up to 5 µM BC1 (Figure 5.7A) or tRNA (Figure 5.7B) to 
cortical lysates fails to compete with the in vivo binding site of FMRP on polyribosomes 
and displace it.  Moreover, although BC1 has been shown to be involved in the global 
regulation of translation (Wang et al., 2005), the polyribosome profile and rpS6 
distribution do not change in the presence of a vast excess of this RNA.  Other 
researchers have found no significant interaction between FMRP and BC1 (Wang et al., 
2005).  Our results demonstrate that FMRP is specifically associated with brain 
























Figure 5.7 BC1 RNA and yeast tRNA do not disrupt FMRP interaction with 
polyribosomes. A254 traces (A) and Western blot analysis for FMRP or ribosomal S6 
protein (B), as in Figure 6. No RNA was added to the control lysates (control). BC1 RNA 
(produced by in vitro transcription and gel purified) and yeast tRNA at the indicated 






































kcRNA cross-links directly to FMRP in brain lysate 
 Despite the fact that FMRP binds kcRNA with high affinity in vitro, the 
possibility remains that kcRNA disrupts FMRP:polyribosome complexes by some 
mechanism that does not involve stable binding to FMRP.  For example, in brain lysate, 
kcRNA could act as a “toxic” aptamer, transiently binding FMRP and releasing a 
denatured protein. Alternatively, kcRNA could interfere with the FMRP binding site in 
translating mRNAs.  In order to address this question and confirm FMRP:kcRNA 
complex formation in brain lysate, we used cross-linking immunoprecipitation (CLIP) to 
assess whether there is a direct interaction between protein and RNA.  CLIP has been 
developed and optimized by our lab as a method for rapid identification of in vivo targets 
of RNA-binding proteins. (Ule et al., 2005a)  FMRP-specific modifications to this 
protocol have been developed by J. Zang and J. C. Darnell (unpublished data.)  For this 
experiment, a post-mitochondrial supernatant was prepared from wild type or FMR1 
knockout mouse cerebral cortex, and divided into two tubes.  One set of wild type and 
knockout lysates was incubated with 500nM kc7 RNA for 15 minutes at room 
temperature. Each sample was then loaded on a 20-50% sucrose gradient, centrifuged and 
collected into 16 fractions using standard polyribosome protocols.  After fraction 
collection, the first 6 fractions of each gradient were divided equally, and protein from an 
aliquot precipitated for Western blot analysis.  One half of each fraction was brought to 
30mM EDTA, mixed, and placed on ice.  Both sets of gradient fractions (intact and 
EDTA-treated) were exposed to UV cross-linking (6 X 4000J) while kept on ice and 
swirled before each UV exposure.  Fractions 1-3 from each gradient and condition were 
pooled and FMRP:RNA complexes were immunoprecipitated using mixed monoclonal 
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and bridging antibodies with Protein A Dynabeads (see Chapter II for details).  After 
1:100 digestion with RNase A and a series of stringent washes, radio-labeled RNA 
linkers were ligated to RNAs that remained cross-linked to FMRP.  These RNAs were 
isolated by SDS-PAGE and nitrocellulose blotting (Figure 5.8B), eluted, subjected to 
PCR (Figure 5.8C) and cloned.  Figure 5.8A shows the FMRP distribution in fractions 1-
6 of the wild type (WT) and kc7 RNA treated-wild type (WTkc7) gradients.  As 
expected, there is no signal for FMRP in the knockout (KO) and kc7 RNA treated-
knockout (KOkc7) gradients.  Of the eight sets of fractions (each gradient +/- EDTA), we 
have immunoprecipitated from four: WT+EDTA, WTkc7, WTkc7+EDTA, and 
KOkc7+EDTA.  After immunoprecipitation and RNA ligation, FMRP-RNA complexes 
electrophorese more slowly than non-cross-linked FMRP. Specifically, we can expect 
FMRP cross-linked to a RNA of ~100 nucleotides to migrate at about 33 kilo Daltons 
larger than that of FMRP alone (68-80kDa) ((Ule et al., 2005a); J. Zang, J. Ule, and A. 
Mele, unpublished data.)  Figure 5.8B is an autoradiograph from labeled FMRP:RNA 
complexes that have been transferred to nitrocellulose after electrophoresis.  Specific 
bands are visible which correspond to specific RNA species.  A band between 
approximately 120kDa and 140kDa (asterisk) is just visible in the WT+EDTA and 
KOkc7+EDTA lanes.  This is a non-specific band that is neither kc7- nor FMRP-
dependent.  (It represents contaminating immunoprecipitation of Ago2:miRNA 
complexes by the 7G1-1 monoclonal antibody against FMRP that cross-reacts with Ago2 
(J. Zang, unpublished data.))   
A dark band of ~90-100kDa (§) is visible in the WTkc7 and WT kc7+EDTA 
















Figure 5.8 kc7 RNA cross-links to FMRP in sucrose gradients. (A) Western blots 
against FMRP of fractions 1-6 (of 16) of FMRP wild type and knockout mouse cortex 
polyribosomal gradients.  Fractions 1-3 from each gradient are pooled for 
immunoprecipitation in (B), an autoradiogram of a nitrocellulose membrane showing 
radiolabeled RNA crosslinked to immunoprecipitating proteins. Arrowhead indicates the 
expected migration of non-crosslinked FMRP.  Lettered bands were cut out of the 

















































kc7 RNA.  In fact, a closer look at these sequences reveals that every sequence includes 
either of the two “kissing” nucleotides (G23 and C64 in kc7, the equivalent of G23 and 
C66 in kc2 and G20 and C45 in Δkc2), as shown in Table 5.1. This data from an unbiased 
screen supports previous biochemical data describing the sequence and structure 
specificities of kissing complex RNA folding and interaction with FMRP. (Darnell et al., 
2005a)  The remaining nine sequences from this band are six ribosomal RNAs, one 
miRNA, one intronic sequence, and one clone of repeat sequence from genomic DNA.  
Notably, kc7 sequences were not found among the KOkc7+EDTA and WTkc7+EDTA 
CLIP tags.  This indicates that magnesium can be chelated by addition of EDTA when 
FMRP has first been incubated with kc7 RNA, and that this chelation disrupts the 
FMRP:kc7 interaction, preventing subsequent cross-linking.   
The WTkc7+EDTA autoradiograph in Figure 5.8B while very dark, seems to 
contain many bands of different sizes, all of which were cloned and sequenced.  18 of 23 
CLIP tags from this lane were identified as ribosomal RNAs.  These sequences map to 
many regions of the full-length 18S and 28S rRNAs.  It is possible that FMRP may 
interact with ribosomal RNA in vivo.  Indeed there is a report that FMRP associates with 
the large subunit of the ribosome (Siomi et al., 1996), and there are 6 rRNA CLIP tags 
identified from the intact WTkc7 CLIP.  However, it is more likely that as a “sticky” 
RNA-binding protein newly dissociated from its RNA cargoes by the combination of kc7 
followed by EDTA, it is now able to bind to rRNAs, present in great abundance in the 
cell.  Moreover, EDTA treatment also disrupts the ribosome, exposing surfaces of rRNAs 
that are normally inaccessible to FMRP.  In addition, rRNAs are the most frequent non-
specific “contaminating” RNAs identified by CLIP for several RNA-binding proteins (J. 
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Zang, A. Mele, and J. Ule, unpublished data.)  Thus, in the absence of a particular over-
enriched sequence from either the 18S or 28S species in the resulting CLIP tags, this 
interaction may be an artifact and not biologically relevant.  Taken together, these data 
indicate that FMRP interacts directly with the kcRNA pseudoknot in brain lysate, that 
this interaction is stable enough to persist through a two-hour centrifugation and fraction 
collection, and that EDTA disrupts this interaction. 
 






kc7 sequence - - 17 - 
         3’ hairpin (includes C64)   16  
         5’ hairpin (includes G23)   1  
rRNA 6 - 6 18 
        18S rRNA 0  2 16 
        28S rRNA 6  4 2 
mRNA 2† - - 4† 
miRNA 1 - 1 1 
snRNA - 1 - - 
other* 2 1 2 - 
# sequenced 32 4 46 53 
Total CLIP tags 11 2 26 23 
 
Table 5.1  Classification of kc7-shifted FMRP CLIP tags. 
Sequences cloned from bands in Figure 5.8C were identified by BLAT (UCSC) and 
NCBI BLAST.  Of the total number of clones sequenced, many represented vector 
religation or primer-primer ligation events.  As such the total number of identifiable 
sequences is given as Total CLIP tags.  *other sequences include: mitochondrial DNA 
(1), genomic DNA (3), intron RNA (1).  †mRNAs: cat eye syndrome chromosome region 
candidate 6 (Cecr6), cytidine monophospho-N-acetylneuraminic acid synthetase (Cmas), 




Recombinant KH2 as a competitor for polyribosome association 
 FMRP:polyribosome complexes can be dissociated by an RNA competitor for 
KH2 binding.  Therefore, the converse question is relevant: can increased concentrations 
of recombinant KH2 compete for endogenous kissing complex-type binding sites on 
polyribosomes and thereby displace endogenous FMRP?  If so, KH2 could act as a 
dominant negative protein that could potentially serve as a tool to inhibit FMRP function 
in vivo.  To test this hypothesis, we purified two types of recombinant FMRP KH2, a 
construct encoding the minimal sequence necessary to bind kcRNA that lacks exons 11 
and 12 (KH2 –e11, 12), and a protein that includes the variable loop of exon 11 within 
the KH2 domain (KH2 –e12).  Incubation of either of these KH2 isoforms at 
concentrations from 500nM to 18µM does not alter the distribution of FMRP (Figure 
5.9B, C).  As a control, these protein preparations were tested for in vitro kcRNA-binding 
ability by filter binding assay. The affinity of KH2 for kc7 RNA has previously been 
measured as approximately 35nM (Darnell et al., 2005a).  From the binding curves in 
Figure 5.9A, the Kd for KH2 (-e11,12) is ~27nM, and the Kd for KH2 (-e12) is ~45nM.  
Thus, these preparations of both KH2 isoforms are able to bind kc7 with the expected 
affinity, and the presence of exon11 does not affect this binding. While this experiment 
shows that using recombinant KH2 as a spiked-in competitor for endogenous KH2 target 
RNAs does not disrupt FMRP:polyribosome complexes, there are many caveats to this 
result.  First, kcRNA is an in vitro selected aptamer that, by definition, will have the 
highest possible affinity for KH2.  Therefore, it is a reasonable possibility that 


















Figure 5.9 Recombinant KH2 does not shift endogenous FMRP off polyribosomes. 
(A) Filter binding assays of two preparations of recombinant KH2 (-e11, 12) and (-e12) 
show that these preparations bind kc7 RNA with the expected affinity in vitro (~30nM).  
(B, C) Western blots for FMRP from mouse cortex polyribosome gradients that have 
been treated with various concentrations of recombinant KH2 isoforms. 
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our assay. However, recombinant KH2 and full-length FMRP have the same in vitro 
affinity for kcRNA.  Thus, when competing with endogenous FMRP in brain lysate, 
recombinant KH2 does not have the advantage of a higher affinity for RNA targets.  
Second, there are as yet no data describing the mechanism by which FMRP binds in vivo 
mRNA targets.  This process may very well involve other domains in FMRP as discussed 
earlier, perhaps in a helicase-type manner that allows another domain to bind an 
otherwise hidden site.  Or, multiple domains may be required for enhanced stability of the 
FMRP:mRNA interaction, perhaps involving several binding sites on a single mRNA.  
As a single RNA-binding domain spiked into a cytoplasmic lysate, recombinant KH2 
does not see the same opportunities for binding mRNAs during the course of normal 
processing events.  Finally, KH2 has been shown to be important for heterodimerization 
of FMRP with FXR2. (Feng et al., 1997a)  This suggests that spiked-in KH2 may be 
sequestered by protein-protein interactions and therefore fail to bind endogenous mRNA 
targets.  An alternative scenario hinges on the likelihood that FMRP may bind its mRNA 
targets in the nucleus and participate in their export, transport, and translation.  All of 
these issues bear investigation.  Further study is warranted to more precisely elucidate the 
role of the KH2 domain in FMRP function. 
 
Discussion 
Fragile-X mental retardation results from mutations that lead to loss of FMRP 
function.  In particular, the substitution of an arginine for a conserved isoleucine in the 
second KH domain results in a severe form of Fragile-X mental retardation syndrome, 
and abrogates polyribosome association (De Boulle et al., 1993; Feng et al., 1997a).  
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However, there have been various interpretations of the latter observation, including 
suggestions that the I304N mutation interferes with protein homodimerization 
(Laggerbauer et al., 2001), disrupts heterodimerization with FXR2 (Feng et al., 1997a), 
causes protein instability (Musco et al., 1996), or abrogates sequence-specific RNA 
binding (Lewis et al., 2000; Ramos et al., 2003a).  To specifically target the contributions 
of KH2 to normal FMRP function in neurons, we have used high affinity RNA ligands to 
compete for binding to either the KH2 or RGG RNA-binding domain.  The kissing 
complex ligand for KH2 is a unique structure motif that offers clues to the mechanism of 
FMRP interaction with polyribosomes.  The I304N mutant FMRP is associated with 
abnormally small mRNPs rather than polyribosomes (Feng et al., 1997a), and does not 
bind kissing complex RNAs in vitro (Darnell et al., 2005a).  We find that the association 
of FMRP with brain polyribosomes is specifically competed by the KH2 kissing complex 
RNA, but not by G-quartet RNAs that bind to the FMRP RGG domain. Therefore, the 
FMRP:kissing complex RNA interaction links the neurologic disease of Fragile-X 
syndrome and the potential role of FMRP in translational regulation. 
Biologically relevant kissing loop-loop interactions were first described in tRNA. 
(Kim et al., 1974; Moras et al., 1980)  This subset of loop-loop pseudoknots can be 
intramolecular, as for tRNA, or intermolecular, such as the HIV RNA genome, which 
dimerizes via the stem loop of the DIS region. (Paillart et al., 1996)   The bicoid mRNA 
homodimerizes via loop-loop interactions between 3’ UTRs of two bicoid messages.  
This dimerization is required for interaction with Staufen and localization to the anterior 
pole of the Drosophila embryo. (Ferrandon et al., 1997) It is possible that FMRP could 
bind to two stem-loops on different RNA molecules present in high enough local 
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concentration.  However, our data indicate that an intramolecular kissing complex is 
required for interaction with KH2. 
There are several examples of loop-loop interactions that suppress translation in 
vivo. In the yeast Hac1 mRNA, a site in the 3’UTR forms a duplex with a stem loop in a 
retained intron, causing translating polyribosomes to stall. (Chapman and Walter, 1997; 
Ruegsegger et al., 2001)  In prokaryotes, two small non-translated RNAs, OxyS and 
CopA, are complementary to 5' noncoding sequences of target mRNAs, and form 
intermolecular kissing complexes that suppress translation. (Argaman and Altuvia, 2000; 
Kolb et al., 2000)  The FMRP:kissing complex may stabilize the interaction of two stem-
loops in a single mRNA or in distinct messages.  It is also possible FMRP is involved in 
the mechanism of translation inhibition by miRNAs by means of this type of structure.   
These results predict that the in vivo RNA target(s) of FMRP KH domains harbor 
kissing complex motifs.  Ongoing efforts in our lab and others aim to develop a 
bioinformatic screen for this complex structure- and sequence- specific motif.  In 
addition, it is possible that previously identified FMRP targets may contain one or both 
stem-loops of a functional kissing complex. 
FMRP interacts with a number of RNA-binding proteins, some of which are also 
associated with polyribosomes (see Chapter 6 for discussion and references.)   As such, it 
has been suggested that FMRP may bind to polyribosomes indirectly, perhaps through 
another protein:RNA complex or through interaction with components of the RISC 
complex and/or miRNAs.  However, our data support the direct association of FMRP 
with RNAs that contain a kissing complex motif, and that are bound by ribosomes. 
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FMRP may independently bind RNAs harboring G-quartets or kissing complex 
motifs, or may interact with both motifs at the same time.  Such interactions could be in 
trans, such that FMRP binds both motifs in independent RNA molecules, facilitating 
interaction between different RNA-protein complexes. Alternatively, FMRP may bind 
single transcripts harboring both G-quartet and kissing complex RNA targets.  
Furthermore the combination of these distinct binding sites may be key to the overall 
function of FMRP.  While KH2 binding to kissing complex RNA allows FMRP to 
interact with polyribosomes, the RGG:G-quartet complex may influence translational 
regulation by an additional or complementary mechanism.  Moreover, G-quartet RNA 
binding by FMRP may also be involved in other aspects of the export and localization of 
target mRNAs. 
We have found that kissing complex RNA is able to displace FMRP from 
polyribosomes at ~100-nM concentration. This disruption is very specific for the kcRNA 
ligand, since FMRP polyribosome association is not affected by kcRNA harboring a 
single point mutation, nor by 50-fold higher concentrations of G-quartet RNA, tRNA, or 
BC1 RNA. These observations clearly indicate that the ability of the KH2 domain to 
specifically bind kcRNA is critical for the association of FMRP with brain polyribosomes 
and may be central to the molecular pathophysiology of Fragile X syndrome.  
 
Acknowledgements 
Jennifer Darnell identified and characterized both high affinity RNA ligands for 
FMRP.  Without this meticulous and ground-breaking work, I would not have been able 
to do the experiments discussed here.  In addition, Jennifer’s suggestions, reagents, 
 97 
protocols, and general enthusiasm throughout much of this work have been invaluable.  
Julie Zang and Jennifer optimized the CLIP protocol for FMRP.  Jennifer provided the 








Local control of protein synthesis in specific sub-cellular domains is an important 
aspect of the regulation of gene expression in neurons.  In particular, regulation of 
translation at post-synaptic sites plays a role in activity-dependent synaptic changes.  A 
number of RNA-binding proteins have been shown to regulate the translation of their 
target mRNAs.  One family of candidate RNA-binding proteins for this regulatory role in 
neurons is the Fragile X related (FXR) family of FMRP, and the Fragile X mental 
retardation-related proteins 1 and 2 (FXR1 and FXR2).  The absence of FMRP or FXR2 
produces a neurologic phenotype in mouse models, and these proteins have been 
localized to sub-synaptic areas of dendrites.   
The phenotype of fragile X syndrome includes mild to severe cognitive deficits, 
attention-deficit hyperactivity disorder, autistic-like behavior, abnormal facial features 
such as a prominent jaw and large ears, macroorchidism in postpubescent males, and 
some connective tissue abnormalities. Fmr1 knockout mice have subtle defects in 
behavior, learning and motor coordination, as well as an increased sensitivity to 
audiogenic epileptic seizures, and increased anxiety.  FMRP is normally expressed in 
most tissues at variable levels, although the highest expression is observed in brain and 
testis.  Despite the presence of an NLS, the majority of FMRP is located in the 
cytoplasm.  FMRP has been shown to shuttle between the nucleus and cytoplasm and has 
been localized to polyribosomes at synapses in neurons. Since FMRP is associated with 
polyribosomes at synapses, and since the FMRP null phenotype includes cognitive 
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impairment and synaptic abnormalities, FMRP may be involved in the regulation of local 
translation in neurons. (Reviewed in (O'Donnell and Warren, 2002; Willemsen et al., 
2004).) 
FMRP has two autosomal paralogs, FXR1 and FXR2, which share >60% amino 
acid identity.  Like FMRP, both FXR1 and FXR2 include two N-terminal tandem KH-
type RNA-binding domains, as well as an RG-rich region in the C-terminal region.  
However, if one considers only the two KH domains, the percentage of conserved similar 
residues rises to 90% (Figure 6.1).  (The extended variable loop for FMRP is dispensible 
for RNA binding by KH2 and has been excluded from this comparison (Darnell et al., 
2005a).)  In contrast, the RG-rich regions of FXR1 and FXR2 are less than 40% identical 
to that of FMRP (Figure 6.2).  Both FXR1 and FXR2 have been shown to associate with 
polyribosomes in the presence or absence of FMRP. (Corbin et al., 1997; Feng et al., 
1997a)  In addition, FMRP can heterodimerize with FXR1 and FXR2, an interaction that 
is not RNA-dependent, but may involve the KH domains of both partners. (Siomi et al., 
1994)   
Like FMRP, FXR2 is expressed in the brain and testes, with the majority of 
protein in the cytoplasm.  Fxr2-null mice display increased hyperactivity, impaired motor 
coordination, impaired fear conditioning, and decreased ability to locate the platform in 
the Morris water maze. (Bontekoe et al., 2002)   In contrast, FXR1 is the only family 
member with a critical role in skeletal and cardiac muscle development and function.  
FXR1 is localized to costameres within muscle fibers, and is important for proper 
localization of vinculin, dystrophin and alpha-actinin.  It has been suggested that FXR1 















Figure 6.1 Alignment of minimal KH domains of mammalian FXR family members 











H FMRP KH2 {-e11 and 12}
10 20 30
F S E D S V Q V P R N L V G K V I G K N G K V I Q E I V D K
F V E D F I Q V P R N L V G K V I G K N G K V I Q E I V D K
F A E D V I Q V P R N L V G K V I G K N G K L I Q E I V D K
F . E D I Q V P R N L V G K V I G K N G K V I Q E I V D K
H FXR2 KH2
H FXR1 KH2
H FMRP KH2 {-e11 and 12}
40 50 60
S G V V R V R V E G D N D K K N P R E E G M V P F I F V G T
S G V V R V R I E G D N E N K L P R E D G M V P F V F V G T
S G V V R V R I E A E N E K N V P Q E E G M V P F V F V G T
S G V V R V R I E G D N E K K . P R E E G M V P F V F V G T
H FXR2 KH2
H FXR1 KH2
H FMRP KH2 {-e11 and 12}
70 80 90
R E N I S N A Q A L L E Y H L S Y L
K E S I G N V Q V L L E Y H I A Y L
K D S I A N A T V L L D Y H L N Y L











































Figure 6.2  Alignment of C-terminal regions from mammalian and fly FXR family 




cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
10 20 30
K E V D Q L R L E R L Q I D E Q L R Q I G A S S R P P P N R
K E V E Q L R M E R L Q I D E Q L R Q I G S - - R - - - - -
Q E V E Q L R L E R L Q I D E Q L R Q I G L G F R P P G S G
K E V E Q L R Q E K M E I D Q Q L R A I Q E S S M G S T Q S
K E V E Q L R E R L Q I D E Q L R Q I G S S R P P
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
40 50 60
- - - - T D K E K S Y V T D D G Q G M G - R G S R - - - - P
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - S
R G S G G S D K A G Y S T D E S S S S S L H A T R T Y G G S
F P V T R R S E R G Y S S D I E S V R S M R G G G - - - G G
E G Y S T D S S R G R T Y G G
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
70 80 90
Y R N R G H G R R - - G P G Y T S G T N S E A S N A S E T E
Y S G R G R G R R G P N Y T S G Y G T N S E L S N P S E T E
Y G G R G R G R R - - T G G P A Y G P S S D V S T A S E T E
Q R G R V R G R G G G G P G G G N G L N Q R Y H N N R R D E
Y G R G R G R R G G . G N S . . S N S E T E
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
100 110 120
S D H R D E L S D W S L A P T E E E R E S F L R R G - D - -
S E R K D E L S D W S L A G - E D N R D - - S R H Q R D - -
S E K R E - - - E P N R A G - P G D R D P P T R G E - E - -
D D Y N S - - - R G D H Q R - D Q Q R G Y N D R G G G D N T
S . . . . E L S . A T . R . R D N T
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
130 140 150
G R R R G - - - - - - - G G G R G Q G G R - - - - - - G R G
S R R R P G G R G R S V S G G R G R G G P - - - - - - - R G
S R R R P - - - - - - - T G G R G R G P P P A P R P T S R Y
G S Y R G - - - - - - - - G G G G A G G P G - - - - N N R R
R R R G G R G R S V G G R G G G P A P R P R
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
160 170 180
G G - - F K - - - G N - D - - - - - - - D H S R T D - - N -
G K S S I S S V L K D P D S N P Y S L L D N T E S D Q T A D
N S S S I S S V L K D P D S N P Y S L L D T S E P E P P V D
G G - - I N R R P P R N D - - Q Q N G R D Y Q H H N - H T T
G S S I S V L P D S N P Y S L L D . . D
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
190 200 210
- R P R N P - - - - - - - R E A K G R T T D G S L Q I R V D
T D A S E S H H S T N R R R R S R R R R T D - E D A V L M D
S E P G E P P P A S A R R R R S R R R R T D - E D R T V M D
E E V R E T R E M S S V E R A D S N S S Y E G S S R R R R R
. E S R R R . R T D G D
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
220 230 240
C N N E R - - - S V H T K T L Q N T S S E G S R L R T G K D
G M T E S D T A S V N E N G L V T V A D Y I S R A E S Q S R
G G L E S D G P N M T E N G L E D E S R P Q R R N R S R R R
Q K N N N G P S N T N G A V A N N N N K P Q S A Q Q P Q Q Q
E D . L S R .
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
250 260 270
R - - - - - - - - - - N - - - Q K - - - - - - - - - - K E K
Q - R - - N L P R E T L A K N K K - - - - - - - - E M A K D
R N R G - N R T D G S I S G D R Q P V T V A D Y I S R A E S
Q P P A P G N K A A L N A G D A S K Q N S - - - - G N A N A
R P N A G D A D Y I A
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
280 290 300
- - - - - - P - - - - - - - - D S V D G - - - - - - - - - -
V I E E H G P S E K A I N G P T S A S G - - - - - - - - - -
Q S R Q S A P L E R T K P S E D S L S G Q K G - - - - - - -
A G G A S K P K D A S R N G D K Q Q A G T Q Q Q Q P S Q V Q
S P E N G S . G Q Q P S Q V Q
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
310 320 330
- - - - - Q Q P - - - - - - - - - - - - - - - - - - - - - -
- - D D I S K L Q R T P - - G E E K I N - - - - - - - - - T
- - D S V S K L P K G P - - S E - - - N - - - - - - - - - G
Q Q Q A A Q Q Q Q P K P R R N K N R S N N H T D Q P S G Q Q
Q Q D . Q P R R E N N H T D Q P S G Q
cterm   FMRP
cterm   FXR1
cterm   FXR2
cterm   fly
340 350 360
- - - - - - - - - - L V N G V P
L K E E N T Q E A A V L N G V S
E L S A P L E L G S M V N G V S
Q L A E N V K K E G L V N G T S
L E N . V N G V S
 102 
mRNAs.  In addition to skeletal and cardiac muscle, FXR1 is highly expressed in the 
central nervous system and gonads.  Fxr1-knockout mice die shortly after birth, likely 
due to cardiac or respiratory failure.  Mice homozygous for a hypomorphic allele of Fxr1, 
Fxr1+neo, show reduced expression of FXR1 protein, and live for several months after 
birth.  Due to severely impaired muscle development, behavioral analysis of these mice 
has not been attempted. (Mientjes et al., 2004)  An investigation of the CNS role of 
FXR1 requires a tissue-specific conditional knockout.  There are no known human 
diseases due to mutations in either Fxr2 or Fxr1. 
 It has been suggested that the FXR family members may display significant 
functional redundancy in the cells where they are co-expressed.  This is supported by the 
subtle neurologic phenotypes observed in mice that lack FMRP or FXR2.  Thus, a double 
knockout may reveal a more obvious phenotype, and provide additional clues to the roles 
of both proteins.  Fmr1/Fxr2 double-knockout mice have been generated by the Nelson 
and Oostra laboratories.  Compared to single knockout littermates, these mice exhibit 
increased hyperactivity in the open field test, decreased habituation to a novel 
environment, decreased prepulse inhibition to an acoustic startle, and impaired fear 
conditioning. (Spencer et al., 2006) 
 The Drosophila genome contains a single homolog of the FXR family, dfmr.  This 
protein does not contain a functional RGG box (J. C. Darnell, manuscript in preparation); 
however, the two KH-type RNA-binding domains of dFmr are highly conserved through 
mouse and human homologs.  dfmr mutant flies exhibit defects in neurite extension, 
branching and guidance. (Michel et al., 2004; Morales et al., 2002)  In addition, they 
display arrhythmic circadian activity (Dockendorff et al., 2002; Inoue et al., 2002) and an 
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inability to maintain courtship interest. (Dockendorff et al., 2002)  The alterations in 
circadian rhythm of dfmr mutant flies echo the sleep disturbances characteristic of some 
patients with Fragile-X syndrome (Gould et al., 2000).  Thus, there is evidence that, in 
addition to a highly conserved sequence, the three FXR family members in mammals 
may share similar functions in neurons.   
We have recently shown that FMRP binds to kissing complex RNA (kcRNA) via 
KH2, and that the FMRP:polyribosome complex can be disrupted by excess amounts of 
kcRNA.  Since the KH domains of all three FXR family members are so highly 
conserved, it is of interest to test whether FXR1 and FXR2 behave in the same manner.  
FXR1 and FXR2 heterodimerize with FMRP, and may be dissociated from 
polyribosomes by kcRNA for three reasons.  First, they may be shifted off polyribosomes 
when their protein-protein binding partner, FMRP, loses its association with an mRNA 
undergoing translation.  In this case, the heterodimer would remain intact, but RNA 
binding by FMRP KH2 would be disrupted.  Second, kcRNA may disrupt the protein-
protein interaction between FMRP and FXR1 or FXR2.  Here, both proteins would shift 
off polyribosomes, but their ability to interact would be abrogated.  Third, if the KH2 
domain of FXR1 and/or FXR2 is able to bind kcRNA directly, kcRNA will disrupt the 
association of these proteins with polyribosomes.  More importantly, this effect will be 
observed in brain lysates of both wild type and Fmr1 knockout mice.   Our data support 
the third possibility, and suggest that the KH2 domains of FMRP, FXR1 and FXR2 
associate with polyribosomes via kissing complex RNA motifs. 
 In addition to FXR1 and FXR2, FMRP has been identified as a binding partner 
for many proteins, some of which also bind RNA and/or are associated with 
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polyribosomes.  Notable interactors include: NUFIP1 (Bardoni et al., 1999; Bardoni et 
al., 2003b); CYFIP1 and CYFIP2 (Schenck et al., 2001); 82-FIP (Bardoni et al., 2003a); 
Nucleolin (Ceman et al., 1999); YB1 (Ceman et al., 2000); Pur α, mStaufen and Myosin 
Va (Ohashi et al., 2002); microspherule protein 58 (Davidovic et al., 2006); PAR6, mLgl 
and aPKCζ (Zarnescu et al., 2005); ribosomal proteins L5 and L11; Dmp68 (Ishizuka et 
al., 2002); and the Argonaute protein Ago2 (eIF2C2) (Caudy et al., 2002; Ishizuka et al., 
2002; Jin et al., 2004).  Our high-affinity RNA ligands for the KH2 and RGG domains of 
FMRP are useful tools to study the whether these domains are required for interaction 
with the above proteins, and whether any of these interacting proteins remain associated 
with FMRP even after it has been dissociated from polyribosomes by kcRNA. 
 Finally, our domain-specific high-affinity RNA ligands, kcRNA and gqRNA, 
represent unique tools to address the contributions of each RNA-binding domain for the 
FXR protein family.  By selectively targeting the RNA-binding ability of KH2, in vivo 
expression of these ligands as “RNA decoys” can overcome the overlapping roles of 




kcRNA dissociates FXR1 and FXR2 from polyribosomes 
The KH domains of FMRP, FXR1 and FXR2 are highly conserved, as shown in 
Figure 6.1, whereas the RG-rich C-terminal regions of these proteins display little 
similarity (Figure 6.2).  In addition FMRP has been shown to interact with both FXR1 
and FXR2.  We have previously shown that FMRP dissociates from polyribosomes when 
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treated with 30mM EDTA or 500nM kcRNA, but not 500nM gqRNA (Chapter 5 and 
(Darnell et al., 2005a)).  For these reasons, we probed Western blots from Figure 5.4 with 
an antibody to FXR2 (1G2).  As shown in Figure 6.3, when a post-mitochondrial 
supernatant from wild type mouse brain is fractionated on a 20-50% sucrose gradient, 
FXR2 cosediments with polyribosomes.  Treatment with EDTA shifts FXR2 to fractions 
3-8 (of 16).  When brain lysate is incubated with kcRNA (500nM kc2), but not gqRNA 
(500nM sc1), FXR2 no longer cosediments with intact polyribosomes.  Thus, the effect 
of an excess of kissing complex RNA is not specific to FMRP, but may extend to other 
FMRP-interacting proteins and/or other proteins able to bind kcRNA. 
 The KH domains of FXR family members are highly conserved from Drosophila 
melanogaster through Homo sapiens. (Morales et al., 2002)  As such, we investigated 
whether human FXR family members also were susceptible to competition by kcRNA.  
IMR-32 cells, originally derived from a human neuroblastoma were lysed with 0.3% 













Figure 6.3 FXR2 is shifted off polyribosomes by EDTA and kissing complex RNA.  
Polyribosome gradient separations were performed from wild type mouse cerebral cortex 
and subjected to incubation with 30mM EDTA, 500nM kc2 RNA or 500nM sc1 RNA.  
Western blots of TCA-precipitated gradient fractions are shown for FXR2.  
 
500nM RNA or an equal volume of RNA-folding buffer, and loaded onto a 20-50% 
sucrose gradient.  Figure 6.4 shows polyribosome profiles (A) and Western blots (B) 
from samples treated with kc2 RNA, mutant kc2 RNA or sc1 RNA.  Both FMRP and 
FXR1 fail to cosediment with polyribosomes in the presence of 500nM kcRNA, but not 
mutant kcRNA or gqRNA.  Therefore, the ability to interact with polyribosomes via 
kcRNA is conserved in mouse and human FXR family members.   
 
FXR1 and FXR2 associate with kcRNA and polyribosomes independently of FMRP  
Additional experiments by J. C. Darnell show that recombinant KH2 domains of 
FXR1 and FXR2 bind kcRNA in vitro, and that this interaction is abrogated by mutations 
in FXR1 and FXR2 that are analogous to the FMRP I304N mutation in KH2 (data not 
shown).  Moreover, the dfmr KH2 domain also binds kcRNA with a similar affinity. The 
KH1 domains of all three family members do not bind kcRNA.  Interestingly, while 
FMRP binds gqRNA with high affinity (Darnell et al., 2001), the C-termini of FXR1 and  
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Figure 6.4 FMRP and FXR1 are competed off polyribosomes by kissing complex 
RNA in human neuroblastoma cells.  UV absorbance profiles (A) and Western blots 
(B) against FMRP and FXR1 for polyribosome gradient fractionations of IMR32 cell 
cytoplasmic extracts.  After cell lysis with hypotonic buffer containing 0.3% NP40, post-
mitochondrial supernatants were incubated with 500nM kc2, mutant kc2, or sc1 RNAs, 
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FXR2 do not bind gqRNA, a result that is supported by the low conservation of these 
domains (Figure 6.2). 
 In order to differentiate between the possibilities that FXR1 and FXR2 might be 
sensitive to kcRNA by direct binding or through their heterodimerization with FMRP, 
kcRNA incubation experiments were performed using cerebral cortices from FMRP 
knockout mice.  Polyribosomal profiles are intact in FMRP knockout mice, with or 
without incubation with 500nM RNA (Figure 6.5A, and ribosomal protein L7 in Figure 
6.5B).  FXR1 and FXR2 cosediment with polyribosomes in the absence of FMRP (Figure 
6.5B).  Incubation of FMRP KO brain lysate with 500nM kc2 RNA results in a shift of 
both FXR1 and FXR2 from bimodal peaks in fractions 3-6 and 9-11 (of 16) to a single 
peak in fractions 1-7.  Interestingly, nine percent each of FXR1 and FXR2 may indeed 
interact with polyribosomes via FMRP, since there is a reproducible shift of these 
proteins when the distributions are compared between samples from FMRP WT and KO 
mice.  However, it is evident in Figure 6.5 that both FXR1 and FXR2 are able to 
associate with polyribosomes by binding kissing complex RNA, irrespective of whether 
FMRP is present. 
 
Unrelated polyribosome-bound proteins do not dissociate with kcRNA 
 To test whether the ability of excess kcRNA to disrupt interaction with 
polyribosomes is specific for the FXR family of RNA-binding proteins, gradient fractions 
from Figure 6.5 were probed for a several neuronal non-FXR RNA-binding proteins.  
Elongation factor 1alpha (EF1α, Figure 6.6A), the neuronal ELAV-related proteins HuB, 







































Figure 6.5 FXR1 and FXR2 are shifted off polyribosomes by kissing complex RNA 
independently of FMRP.  A254 traces (A) and Western blots (B) from polyribosome 
separations of wild type and FMRP knockout mouse cerebral cortices.   Post-
mitochondrial supernatants were incubated with 500nM kc2 (kc2) or mutant kc2 (mut 
kc2) RNAs or RNA binding buffer (Control) before sucrose gradient centrifugation. 
A. 
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Figure 6.6 Control polyribosome-associated proteins do not shift with kissing 
complex RNA.  Western blots of TCA-precipitated gradient fractions shown in Figure 
6.5 (A-C) or a replicate experiment (D) were probed for polyribosome-associated 
proteins that are not known to interact with FMRP: elongation factor 1alpha (A), the 
neuronal Hu proteins HuB, HuC and HuD (B), translation initiation factor 4E (C), and 
Sam68 (Src-associated in mitosis, 68kDa, D). 
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Figure 6.6C) are all unaffected by the absence of FMRP and incubation with kcRNA.  
Fractions from a similar experiment were probed for the RNA splicing and export factor 
Sam68 (Figure 6.6D), which remains bound to polyribosomes in the presence of kcRNA. 
 
Polyribosomal distributions of FMRP-interacting proteins 
 FMRP has been shown to co-precipitate with a large number of neuronal proteins, 
which include nuclear FMRP-interacting protein 1 (NUFIP1) and 82-FIP (Bardoni et al., 
1999; Bardoni et al., 2003b); cytoplasmic FMRP-interacting proteins 1 and 2 (CYFIP1 
and CYFIP2) (Schenck et al., 2001); Nucleolin (Ceman et al., 1999); Y box-binding 
protein 1 (YB1) (Ceman et al., 2000); Pur α, mStaufen and Myosin Va (Ohashi et al., 
2002); the mouse homolog of Drosophila lethal giant larvae (mLgl) and atypical Protein 
Kinase C zeta (aPKCζ) (Zarnescu et al., 2005); ribosomal proteins L5 and L11; Dmp68 
(Ishizuka et al., 2002); poly(ADP-ribose) glycohydrolase (PARG) (Gagne et al., 2005); 
the Argonaute protein Ago2 (eIF2C2) (Caudy et al., 2002; Ishizuka et al., 2002; Jin et al., 
2004); Ran-binding protein 9 (RanBP9/RanBPM) (Menon et al., 2004); and nuclear 
export receptor NXF2 (Lai et al., 2006).  Using antibodies against some of these proteins, 
we have screened Western blots from polyribosome gradients of fractionated wild type or 
FMRP knockout brain lysate treated with kcRNA or gqRNA (Figure 6.7).  Figure 6.7A 
demonstrates that FMRP is shifted off polyribosomes when treated with kcRNA, 
compared to control (-) and gqRNA-treated samples.  (Signal evident in lanes one and 
two of the FMRP knockout samples is non-specific background chemiluminescence due 
to the large amount of protein loaded in these lanes.  These samples are from FMRP 
knockout brain lysate.)  Confirming results shown in Figures 6.3, 6.4 and 6.5, FXR1  
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Figure 6.7 Polyribosome distributions of FMRP-interacting proteins in 
mouse brain. 
Western blots of TCA-precipitated sucrose gradient fractions from wild type or 
FMRP knockout mouse cerebral cortex polyribosomes.  Post-mitochondrial 
cortex supernatants were treated with kc7 RNA (kcRNA), sc1 RNA (gqRNA) or 
RNA binding buffer (-).  The gradient positions of the 80S single ribosome and 
polyribosomes are indicated.  Blots were probed with antibodies to FMRP (A, 
2F5), FXR1 (B, 830), FXR2 (C, 1G2), ribosomal protein P0 (D, Biodesign), Pur 
alpha (E, Abnova), mouse Staufen (F, Chemicon), the neuronal myosin Va (G, 
Sigma), cytoplasmic FMRP-interacting protein 2 (H, courtesy of B. Bardoni), 
nuclear FMRP-interacting protein (I, courtesy of B. Bardoni), Y-box binding 
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 (Figure 6.7B) and FXR2 (Figure 6.7C) cosediment with polyribosomes in the presence 
and absence of FMRP.  This interaction is disrupted by kcRNA, but not gqRNA, in both 
wild type and FMRP knockout cerebral cortex.  The distribution of ribosomal protein P0, 
a component of the 60S subunit, is not altered by a lack of FMRP or incubation with 
kcRNA or gqRNA (Figure 6.7D).   
Ohashi and colleagues identified an mRNP containing FMRP, Purα, mStaufen 
and myosin Va (Ohashi et al., 2002).  This complex is released from polyribosomes by 
EDTA, and is abolished by treatment with RNase.  Purα binds both single-stranded DNA 
and RNA, and is reported to control the expression of BC1 RNA, as well as that of a 
number of other genes. (Kobayashi et al., 2000; Ohashi et al., 2000; Zhang et al., 2005)  
It also cosediments with polyribosomes, and Purα-null mice exhibit impaired neural 
development. (Gallia et al., 2000; Khalili et al., 2003)  Therefore, it has been proposed 
that Purα may assist mRNP assembly in an RNA-dependent manner and be involved in 
targeting mRNPs to polyribosomes in cooperation with other RNA-binding proteins 
(Ohashi et al., 2002).  We find that the majority of cytoplasmic Purα does not cosediment 
with polyribosomes, but is in fact found in the upper region of the gradient, likely in a 
non-polyribosomal mRNP (Figure 6.7E).  However, there is a portion of Purα that is 
found in fractions 4-9 that may be bound to polyribosomes.  This interaction is not 
affected by the loss of FMRP (FMRP KO -), but does exhibit a slight shift in the presence 
of kcRNA, and a more significant shift in the gqRNA-treated gradients.  These shifts do 
not require FMRP, since the kcRNA and gqRNA shifts are comparable between wild 
type and knockout gradients.  This finding clearly demonstrates that cytoplasmic Purα 
interacts with large complexes via RNA, but that this interaction may not be sequence-
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specific.  Further study of the literature reveals that Purα binds G-rich sequences in both 
RNA and single-stranded DNA.  (Gallia et al., 2000)  Since both kcRNA and gqRNA 
contain stretches of multiple G residues (gqRNA more so than kcRNA), it is likely that 
these spiked-in RNAs compete with endogenous targets for binding by Purα.  This may 
be related to FMRP biology in that Purα could be bound to mRNA cargoes that also 
carry FMRP.  It is likely that specific interaction of Purα with an mRNA does not depend 
on the RNA binding abilities of FXR KH domains or the FMRP RGG box. 
mStaufen, the mouse homolog of Drosophila staufen, is an RNA-binding protein 
thought to be involved in mRNA transport and localization.  In addition to the 
coimmunoprecipitation of mStaufen with Purα and FMRP (Ohashi et al., 2002), the Ortin 
laboratory reported that FMRP copurifies with granules containing hStaufen, ribosomes, 
cytoskeletal control proteins, and motor proteins (Villace et al., 2004).  We find that the 
majority of mStaufen is found in fraction 2 (of 12), a region of the 20-50% sucrose 
gradient that contains mRNPs, and possibly 40S ribosomal subunits (Figure 6.7F).  Faint 
bands can be seen in fractions 3-8, indicating that mStaufen may be present on 
polyribosomes, as has been previously reported (Ohashi et al., 2002).  Incubation with 
kcRNA or gqRNA does not appear to alter the distribution of mStaufen in either wild 
type or FMRP knockout cerebral cortex.  
A fourth component of the mRNP containing FMRP, Purα and mStaufen is 
myosin Va, a non-muscle myosin that is expressed in brain and involved in the transport 
of vesicles and mRNAs (Evans et al., 1998).  When centrifuged through a 20-50% 
sucrose gradient, myosin Va exhibits an unusual distribution.  There are two peaks 
present: the first in fraction three, corresponding to mRNPs and the 40S ribosomal 
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subunit, and the second in fractions 10-12, possibly containing large granules and/or 
cytoskeletal networks (Figure 6.7G).  Of note, while others have described an association 
of FMRP with cytoplasmic granules (De Diego Otero et al., 2002; Krichevsky and Kosik, 
2001; Mazroui et al., 2002; Villace et al., 2004), in our hands, this is the first evidence of 
a complex of that size, as assayed by gradient centrifugation.  We do not see a granule 
“peak” in polyribosome profiles from brain and tissue culture cells.  FMRP, FXR1 and 
FXR2 are present in fractions 10-11, but do not display the same peak of protein 
concentration that is seen for myosin Va.  Myosin Va is present in the intervening 
fractions 4-9.  The distribution in fractions 3-9 does not change with the absence of 
FMRP or treatment with kcRNA or gqRNA.  The myosin Va peak in fractions 10-11 
does seem to shift from fraction ten in wild type brain, to fraction eleven in FMRP 
knockout brain.  However, this change in distribution is only one fraction, which could be 
due to technical artifact in gradient fraction collection.  Further analysis requires better 
resolution of these fractions (e.g. a 35-60% sucrose gradient divided into more fractions 
of smaller volume.)  From these data, myosin Va does not display a gross change in 
polyribosome distribution when treated with kcRNA or gqRNA. 
CYFIP1 and CYFIP2 share 88% sequence identity, and contain no known 
functional motifs.  They were first identified as FMRP-interacting proteins through a 
yeast two-hybrid screen (Schenck et al., 2001).  In addition, the Drosophila proteome 
contains a single homolog, CYFIP/Sra-1, that interacts with dFmr1 (Schenck et al., 
2003).  Interestingly, CYFIP1 interacts only with FMRP, while CYFIP2 interacts with all 
three of the FXR family members via the same N-terminal domain that mediates 
heterodimerization between FXR proteins.  CYFIP1 interacts with Rac1 (Kobayashi et 
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al., 1998), a Rho GTPase, and both family members are thought to regulate actin 
polymerization to shape synapse morphology as part of the WAVE/SCAR complex (Kim 
et al., 2006; Pilpel and Segal, 2005; Schenck et al., 2004)  We find that a small amount of 
CYFIP2 cosediments with polyribosomes in an FMRP-independent manner (Figure 
6.7H).  Incubation with kcRNA or gqRNA does not alter this distribution. 
Nuclear FMRP-interacting protein 1 (NUFIP1) is a nucleocytoplasmic shuttling 
protein predominantly found in the nucleus.   However, it has been co-localized with 
subsynaptic polyribosomes by electron microscopy (Bardoni et al., 2003b).  NUFIP1 
interacts with the N-terminal region of FMRP involved in heterodimerization and binds 
ribohomopolymers in vitro, specifically poly(G) and poly(U) (Bardoni et al., 1999).  In 
contrast to the co-localization of NUFIP1 with polyribosomes, we find that NUFIP1 does 
not cosediment with polyribosomes in brain lysate from either wild type or FMRP 
knockout mice (Figure 6.7I).  These findings are not mutually exclusive, as NUFIP1 may 
be incorporated in mRNPs that are translationally repressed and in a reserve pool at the 
synapse.  Furthermore, unlike Purα, NUFIP1 distribution does not change when 
incubated with kcRNA or gqRNA, even though NUFIP1 also binds G-rich RNA 
(Bardoni et al., 1999).  Perhaps NUFIP1 is part of a translationally silent mRNP that 
includes FMRP, and that is important for correct transport and localization of a given 
mRNA.  Interestingly, NUFIP1 does not interact with FXR1 or FXR2 in a pull-down 
assay (Bardoni et al., 1999), and may compete for binding to FMRP. 
The coimmunoprecipitation of Y box-binding protein 1 (YB1) with FMRP is 
RNA-independent (Ceman et al., 2000).  YB1 is both a transcription factor and a core 
element of mRNP complexes, specifically a component of both translationally repressed 
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and actively translating mRNPs.  (Kohno et al., 2003)  In the polyribosome gradient 
fractionations shown in Figure 6.7J, cytoplasmic YB1 cosediments with small mRNPs; it 
does not seem to be associated with polyribosomes.   
dFmr1 interacts both genetically and biochemically with PAR complex members 
PAR6, dLgl, and aPKCζ (Zarnescu et al., 2005).  This relationship is conserved for the 
mouse homologs of these proteins.  dlgl is an oncogene and encodes a cytoskeletal 
protein involved in cellular polarity and cytoplasmic transport that is phosphorylated by 
aPKCζ. (Vasioukhin, 2006)  Atypical-PKCζ cosediments primarily with smaller 
complexes irrespective of FMRP genotype, although faint bands are visible in fractions 
4-7 (Figure 6.7K).  Incubation with kcRNA or gqRNA does not alter this distribution.  
Thus, mRNAs associated with both FMRP and the PAR/Lgl/aPKCζ complex are likely 
to be translationally repressed. 
Several groups have identified dAgo2 and the mammalian homolog of dAgo1, 
eIF2C2/hAgo2, in complexes that co-purify respectively with dFmr1 and FMRP. (Caudy 
et al., 2002; Ishizuka et al., 2002; Jin et al., 2004)  The Argonaute proteins are 
components of the RISC complex and bind miRNAs.   They are thought to mediate one 
mechanism of translational repression through miRNA targeting of mRNAs. (Chen and 
Meister, 2005)  Mammalian Ago2 (eIF2C2) has been shown to cosediment with 
polyribosomes from cells in culture (Mourelatos et al., 2002).   Due to specificity of anti-
mammalian Argonaute antibodies (a kind gift of T. Tuschl) for the human homologs of 
these proteins, we could not include mAgo1 and mAgo2 in Figure 6.7.  Instead, human 
neuroblastoma cells (IMR-32) in culture were lysed and treated with 500nM RNA 
(kcRNA, mutant kcRNA or gqRNA) or 30mM EDTA, then analyzed by gradient 
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centrifugation and Western blotting.  hAgo1, a closely related family member of hAgo2, 
is partially associated with polyribosomes, but is not affected by incubation with RNA 
ligands for FMRP (Figure 6.8A).  hAgo2 exhibits a slightly different distribution, with a 
peak in fractions 6-11 which shifts to lighter fractions following treatment with EDTA 

























Figure 6.8 Mammalian Argonaute proteins 1 and 2 are not shifted by FMRP RNA 
ligands in human IMR32 cells.  Western blots from polyribosome gradient 
fractionations in Figure 6.4 were probed for Ago1 (A) and Ago2 (B) (antibodies courtesy 
of T. Tuschl).  20-50% sucrose gradient distributions of hAgo1 and hAgo2 do not shift 
when incubated with 500nM FMRP RNA ligands.  hAgo2 is associated with 
polyribosomes, since the peak in fractions 6-13 (Control, top panel) shifts to the top of 
the gradient when treated with 30mM EDTA. 
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Protein-protein interactions are not disrupted by kcRNA 
While the KH2 domains of FXR1 and FXR2 bind kcRNA directly, and both 
FXR1 and FXR2 are competed off polyribosomes by kcRNA in the absence of FMRP, it 
is possible that incubation with kcRNA can also disrupt the heterodimerization of these 
proteins.  In fact, both KH1 and KH2 have been implicated in heterodimerization (Siomi 
et al., 1994).  To test this hypothesis, immunoprecipitations from wild type mouse 
cerebral cortex lysate for FMRP and an irrelevant antibody to an RNA-binding protein 
(anti-Nova) were performed in the presence of 500nM kc2 RNA or mutant kc2 RNA.  
FXR2 specifically coprecipitates with FMRP when incubated with either RNA (Figure 
6.9).  Thus, the KH2:kcRNA interaction does not disrupt heterodimerization of FMRP 
and FXR2.  To further test this hypothesis, coimmunoprecipitations were carried out in a 
mild isotonic buffer under several different conditions, as shown in Figure 6.10.  To 
control for non-specific interactions, FMRP knockout brain lysate was used with and 
without 500nM kcRNA, and FMRP wild type brain lysate was incubated with a control 
antibody.  Experimental conditions included incubation with 500nM kcRNA, 500nM 
gqRNA, 500nM tRNA, 0.1% deoxycholate (DOC), 30mM EDTA, or RNase A.  FXR1 
coprecipitates with FMRP in all conditions, but shows some background non-specific 
precipitation in the immunoprecipitations from FMRP knockout brain and with a control 
antibody.  FXR2 also coprecipitates with FMRP, but seems to require release from 
polyribosomes for efficient capture. It is interesting that FXR1 exhibits an increased 
interaction with FMRP in the presence of gqRNA versus kcRNA, while FXR2 
coprecipitation with FMRP is greatly reduced by gqRNA compared to kcRNA.  MyoVa 













Figure 6.9 Kissing complex RNA does not abrogate heterodimerization of FMRP 
with FXR2.  Post-mitochondrial supernatant from mouse cerebral cortex (lysed in 1X 
brain polyribosome buffer, see Chapter 2) was treated with 500nM kc2 or mutant kc2 and 
incubated with protein A-sepharose pre-bound to 7G1-1 or control (rabbit anti-Nova) 
antibody for 2 hours at 4°C.  IP matrix was washed twice with lysis buffer and extracted 
by boiling in 1X Laemmli sample buffer (Bio-Rad).  10% of IP eluate (IP), 1% of pre-IP 
lysate (Tot), and 1% of post-IP supernatant (Sup) were analyzed by SDS and Western 
blotting for FMRP (1C3) and FXR2 (1G2). 
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Figure 6.10 Co-immunoprecipitations of FMRP with interacting proteins 
under a variety of treatments. Mouse cerebral cortices from wild type and 
FMRP knockout mice were lysed and post-mitochondrial supernatants were 
prepared as in Figure 6.9.  Lysates were incubated as noted for “IP condition” 
with 500nM of the indicated RNA, 0.1% sodium deoxycholate (DOC), 30mM 
EDTA, 2ug/ml RNase A (RNase), or buffer (blank).  After pre-clearing with 
protein A-sepharose for 30 min at 4°C, aliquots were taken for pre-IP total input 
samples (T).  Lysates were immunoprecipitated with mixture of two monoclonal 
antibodies to FMRP (7G1-1 and 2F5) pre-bound to bridging anti-mouse Fcgamma 
antibody fragment (Jackson Labs):protein A-sepharose.  Control antibody IP 
eliminates both monoclonal antibodies to IP with bridging antibody alone.  IP 
matrices were incubated for 2 hours at 4°C and washed twice with lysis buffer 
before boiling in 1X Laemmli sample buffer.  1% of Input (T), 10% of IP eluate 
(IP), and 1% post-IP supernatant (S) are analyzed by Western blotting with 
antibodies to FMRP (2F5), FXR1 (830, courtesy of B. Bardoni), FXR2 (1G2), 
myosin Va (Sigma), Pur alpha (Abnova), mStaufen (Chemicon), atypical Protein 
Kinase C zeta (Sigma), and ribosomal protein P0 (Biodesign).  (Of note, signal for 





MyoVa capture occurs when treated with deoxycholate, indicating that stringent washes 
may yield a more specific result.  Purα shows maximal coprecipitation with FMRP when 
both proteins are released from polyribosomal complexes, as seen in the EDTA- and 
RNase-treated conditions.  Since the Purα-FMRP interaction has been previously 
reported to be RNA-dependent (Ohashi et al., 2002), perhaps this interaction is an artifact 
of incomplete RNase digestion.  Under these conditions, mStaufen, aPKCζ and ribosomal 
protein P0 do not coimmunoprecipitate with FMRP.  Thus, KH2:kcRNA interaction does 
not disrupt heterodimerization of FXR proteins.  Other FMRP-interacting proteins are 
more difficult to capture using this method.  The effects of kcRNA and gqRNA on these 
interactions remain unclear. 
 
RNA decoys: a tool for domain-specific functional inhibition 
Since it is evident that the highly conserved KH2 domains of all three FXR family 
members bind kissing complex RNA with high affinity, and that only FMRP is able to 
bind g-quartet RNA motifs, these RNAs represent possible tools for domain-specific 
functional inhibition of these proteins in vivo.  However, the in vivo expression of these 
RNAs is not trivial.  Since they are short, non-translated RNAs with significant double-
stranded regions, early attempts to express each high-affinity ligand as an individual 96nt 
species resulted in low expression levels and poor export from the nucleus (data not 
shown).  A scheme for improved expression of these decoy RNAs is based on work by 
the Liebhaber and Taira laboratories.  Their studies have shown that the human 
tRNA(Val) (Kuwabara et al., 2001) and the adenoviral VA1 RNA (Makeyev et al., 2002) 
are expressed at high levels and exported to the cytoplasm. Moreover, RNA sequences of 
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interest can be inserted at various locations within these RNAs without disrupting folding 
or nuclear export.  Both of these RNAs have internal Pol III promoters that should 
increase expression by two to three orders of magnitude greater than that from Pol II 
promoters.  We have constructed RNA decoys using either the tRNA or the VA1 
cassettes, and containing kissing complex or g-quartet RNA motifs. Mfold-predicted 
structures for each species are shown in Figure 6.11 (Zuker, 2003).  Mutations that 
disrupt binding to FMRP are indicated.  In vitro transcribed RNA decoys using both 
cassettes bind purified FMRP with affinities close to those for FMRP SELEX target 
RNAs alone, as shown in Figure 6.12. This is the case when transcribed RNA is gel 
purified, denatured and refolded prior to incubation with recombinant FMRP (Figure 
6.12A, top two panels). It is also true when in vitro transcribed RNA, after buffer 
exchange via G-25 sephacryl, is incubated directly with recombinant FMRP, bypassing 
any denaturation and refolding (Figure 6.12A, bottom panel, and B).  In addition, FMRP 
does not bind tRNA or VA1 RNA alone, and does not bind mutated forms of the RNA 
decoys.  While recombinant FMRP binds tRNA and VA1 cassettes that include kcRNA 
sequences, these RNAs may not function to disrupt FMRP:polyribosome complexes in 
mouse cerebral cortical lysate.  Indeed, Figure 6.13 shows that while 500nM tRNAkc7 
completely disrupts FMRP association with polyribosomes (A), 1uM VA1kc7 has no 
effect (B).  For this reason, the VA1 cassette constructs were not used for further 
experiments. 
To facilitate expression in vivo, tRNA expression constructs were cloned into the 
3’LTR of a lentiviral vector developed by the Trono laboratory (Arrighi et al., 2004).  
This vector (pLVTHM, diagrammed in Figure 6.14) has the advantage of containing an  
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Figure 6.11 Predicted structures of RNA decoy molecules.  Mfold-predicted 
structures of tRNA (A) and VA1 (B) expression cassettes and RNA decoys 
containing kc7 RNA or sc1 RNA sequences.  A mutation that abrogates binding 
to FMRP is indicated for each.  Pink asterisks denote kc7 nucleotides that form 
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Figure 6.12 RNA decoys bind recombinant FMRP in vitro. (A) Filter binding assays 
for tRNA-based RNA decoys using recombinant FMRP KH2 (for kcRNA constructs, 
upper left panel) or C-terminus proteins (for sc1 RNA constructs, upper right panel).  kc7 
and kc2 are positive controls for protein activity.  Upper panels test gel-purified, heat-
denatured and refolded RNAs; binding affinities are listed at middle right panel. Middle 
left panel tests KH2 binding to co-transcriptionally folded RNA decoys (purified twice 
with G-50 sepharose columns, no heat denaturation); binding affinities are listed in figure 
legend. (B) Filter binding assays for co-transcriptionally folded VA1-based RNA decoys 
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Figure 6.13 In vitro transcribed RNA decoys in polyribosome shift assay.  Mouse 
cerebral cortex lysates were prepared for polyribosome fractionation and incubated with 
the indicated concentrations of in vitro transcribed RNAs before sucrose gradient 
centrifugation.  Western blots of TCA-precipitated gradient fractions for FMRP indicate 






























Figure 6.14 Lentiviral expression system for RNA decoys. (A) Schematic illustration 
of pLVTt adapted from D. Trono and colleagues.  The H1 promoter (red box) of 
pLVTHM (D. Trono) in the 3’LTR has been replaced with the tRNA decoy expression 
cassette. (B) Northern blot for RNA decoy expression in 293T cells 40 hours post-
lentiviral transduction with virus encoding empty tRNA cassette (tRNA), tRNAkc7 (tkc), 
tRNAmini-sc1 (tgq), or untransduced (UT).  15ug of total nuclear (N) or cytoplasmic (C) 
RNA was electrophoresed on a denaturing 8% acrylamide/7M urea gel.  After transfer to 
positively charged nylon membrane, blot was probed with P32-labeled anti-sense probe 
to the tRNA expression cassette.  Ladder is single stranded DNA.  Band at bottom of blot 
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GFP reporter and a Tet-operator site adjacent to the RNA decoy cassette.  When 
combined with an additional vector that contains a KRAB repressor fused to a Tet-
repressor protein, expression of RNA decoys can be induced by doxycycline (Szulc et al., 
2006).  Figure 6.14B is a Northern blot from 293T cells transduced with lentivirus 
encoding tRNAkc7 (tkc), tRNAminisc1 (tgq) or the tRNA cassette alone.  An antisense 
probe to the tRNA expression cassette reveals that all three RNAs are transcribed and 
exported to the cytoplasm, although export of tRNAminisc1 is much less efficient than 
either tRNAkc7 or the tRNA cassette. 
In vivo activity of tRNAkc7 and tRNAkc2 was examined by polyribosome 
analysis of transduced cells.  Briefly, high titer lentivirus was produced in packaging 
cells, concentrated, and used to transduce 15cm plates of 293T cells.  This method 
produced approximately 90% EGFP-positive cells.  Forty hours post-transduction, cells 
were lysed and layered on 20-50% sucrose gradients.  Western blots from gradient 
fractions are shown in Figure 6.15A.  FMRP in cells transduced with lentivirus encoding 
tRNAkc7, tRNAkc2, tRNAmutkc2, or the tRNA cassette, remains associated with 
polyribosomes.  Western blots from Figure 6.13A are reproduced here for comparison.  
In order to ensure that these RNAs were expressed, RNA was precipitated from aliquots 
of nuclear and cytoplasmic fractions of the cells used in Figure 6.15A.  Northern blotting 
with an antisense tRNA probe (Figure 6.15B) reveals that the tRNA cassette, tRNAkc7 
and tRNAkc2 RNAs were expressed and exported to the cytoplasm.    
Since tRNA-based RNA decoys are expressed, exported to the cytoplasm, and can 
functionally interact with FMRP in a spike-in assay, it is not clear why these RNAs did 


















Figure 6.15 tRNAkcRNA does not compete FMRP off polyribosomes in vivo.   (A) 
Western blots for FMRP of polyribosomal sucrose gradient centrifugations of 293T cells 
40 hours post-lentiviral transduction with the indicated virus.  Transduction efficiency 
was approximately 90% by GFP expression.  Blots from Figure 6.13A are reproduced 
here for comparison.  (B) RNA precipitated from nuclear and cytoplasmic fractions of 
cells in (A) is analyzed by Northern blotting with an antisense probe to the tRNA 
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concentration of these RNA decoys, the antisense tRNA signal from 10µl pellets of 
transduced cells were compared to a known amount of in vitro transcribed tRNAkc7 
(Figure 6.16A).  In sum, tRNA decoys are present at less than 1nM in transduced cells.  
In contrast, there are approximately six picomoles of FMRP in the post-mitochondrial 
supernatant from one juvenile (postnatal day 8) mouse cerebral cortex (Figure 6.16B). 
The 7G1-1 monoclonal antibody recognizes an epitope in the FMRP-specific variable 
loop of KH2 encoded by exon 11.  7G1-1 recognition of the indicated amounts of protein 
from wild type or FMRP knockout cerebral cortex were compared to known quantities of 
recombinant mouse FMRP KH2 (includes exon 11, but not exon 12.)  A rough 
calculation based on the approximate volume of one mouse cerebral cortex (two 
hemispheres) yields an approximate concentration of 20nM FMRP in brain.  No 
quantitation was done for FXR1 or FXR2, which also bind kcRNA with high affinity.  
Thus, it seems that the tRNA-based system of RNA decoy expression is not sufficient for 
effective functional inhibition of FXR KH2 domains.  This may be due to a combination 
of factors, namely, insufficient decoy expression levels, sequestration of RNA decoys by 
unknown factors, and/or an increased susceptibility of FMRP to kcRNA binding when 
diluted approximately five-fold in brain lysis buffer.  Further work is necessary to 
elucidate these requirements.  Despite the difficulties in creating a viable system of in 
vivo RNA decoys for FXR family members, such an array of tool would be invaluable to 
the study of FMRP, FXR1 and FXR2 function in neurons, and could yield insights into 
the molecular mechanisms of Fragile-X mental retardation syndrome.  Ultimately, a 
kissing complex RNA decoy could be used to create a conditional, KH2 domain-specific 




Figure 6.16 Quantitations of RNA decoy and endogenous FMRP expression. (A) 
Northern blot probed with labeled antisense tRNA expression cassette oligonucleotide of 
RNA from 10ul of packed 293 or 293T cells 40 hours post-lentiviral transduction with 
LVTt virus encoding tRNAmutkc2 (293) or tRNAkc7 (293T).  10 femtomoles of in vitro 
transcribed tRNAkc7 is included for comparison. (B) Western blot for FMRP (7G1-1) 
comparing indicated amounts of mouse brain lysate to recombinant mouse KH2 (includes 




 We find that kissing complex RNA can disrupt the polyribosome association of 
FXR1 and FXR2, as well as FMRP.  In their tandem KH domains, these family members 
share 90% sequence similarity.  Our results indicate that these proteins bind to the same 
RNA motif, both in vitro and in vivo.  Thus it is likely that they share a mechanism of 
action and pool of RNA targets in cells where they are co-expressed, i.e. neurons.  Yet, 
from a common ancestral gene (dfmr1 is representative), FXR family members have 
diverged to include C-terminal regions with only 40% sequence identity.  In addition, 
these domains do not share a target RNA sequence.  Therefore, while FXR1 and FXR2 
are found in some cell types that do not express FMRP, they may also have differing 
roles in neurons.  The potential for homodimerization and heterodimerization between 
these proteins adds another layer to the complexity of possibilities for functional roles 
and RNA targets.  We can imagine that a common mechanism is mediated by KH2 
binding to kissing complex RNA motifs that results in a polyribosome-associated 
complex.  However, the identity of the FXR proteins bound to a given mRNA may 
determine a different translational fate.  Alternatively, additional FMRP-binding sites, 
e.g. G-quartets, may specify a subgroup of mRNAs for a unique purpose at the synapse.  
Except for the negative data presented by our laboratory and the Mihailescu laboratory 
(Zanotti et al., 2006), there is as yet no data on whether the C-terminal domains FXR1 
and FXR2 bind sequence specific RNA structural motifs.  Changes in the protein 
composition of an mRNP are known to influence various steps in mRNA processing, 
transport, and regulation.  These substitutions may accompany spatial changes, for 
example, when cytoplasmic PABC replaces nuclear PABPN1 on the poly(A) tail of an 
mRNA during export from the nucleus. (Reviewed in (Kuhn and Wahle, 2004)).  
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Changes in mRNP composition can also result from upstream signal transduction.  For 
example, when nutrients are scarce, cells can restrict translational apparatus to only those 
transcripts necessary for survival in a quiescent state.  This is accomplished using a 
general regulator of translation, Target of Rapamycin (mTOR). (Reviewed in (Hay and 
Sonenberg, 2004)  Briefly, the presence of nutrients and/or growth factors activates 
mTOR, a kinase which phosphorylates eukaryotic translation initiation factor 4E (eIF4E)-
binding proteins (4E-BPs), as well as other proteins involved in translational regulation.  
Phosphorylation of 4E-BP causes its dissociation from eIF4E and allows  eIF4G binding 
that results in 40S ribosome subunit recruitment to the m7G-cap of an mRNA.  Since 
eIF4E is required for cap-dependent translation, this is a general mechanism to regulate 
translation of most mRNAs. In neurons, cytoplasmic polyadenylation element (CPE)-
containing mRNAs are bound by CPE-binding protein (CPEB) and maskin for transport 
into dendrites.  Maskin also binds eIF4E, preventing interaction with eIF4G.  When 
NMDA receptors are stimulated at synapses, Aurora A kinase is activated and 
phosphorylates CPEB, which induces mRNA polyadenylation and likely leads to 
dissociation of maskin from eIF4E, resulting translation of the mRNA. (Huang et al., 
2002; Wu et al., 1998)  FXR proteins may regulate translation of mRNA cargoes in a 
spatial-, temporal- and/or signal-transduction-dependent manner.  In Fragile-X patients 
and FMRP knockout mice, the most striking morphological phenotypes in neurons are 
seen in the dendritic spines. (Comery et al., 1997; Hinton et al., 1991; Wisniewski et al., 
1991)  In addition, since there is a documented increase in group I metabotropic 
glutamate receptor (mGluR)-induced long-term depression (LTD) in hippocampal slices 
from FMRP knockout mice (Huber et al., 2002), FMRP activity is thought to be focused 
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at synaptic areas.  It is possible that while FMRP, FXR1 and FXR2 all associate with 
polyribosomes via kissing complex RNA motifs, this association could be spatially or 
temporally specific for each protein.  Indeed, a single kissing complex motif in a given 
mRNA could be sequentially bound by different FXR proteins during its lifetime.  
Finally, data showing that FMRP may be associated with changes in the quantity of 
polyribosomes in synaptoneurosomes in response to treatment with mGluR agonists, 
suggests that FMRP may be a downstream target of signal-transduction cascades induced 
by synaptic activity (Weiler et al., 2004). 
 The overlap in RNA sequence and structure specificity of the KH2 domains of 
FXR1, FXR2 and FMRP suggests that they may exhibit some functional redundancy in 
neurons.  Fmr1-null mice have normal levels and subcellular distributions of FXR1 and 
FXR2 (Bakker et al., 2000).  Yet, Fragile-X patients and Fmr1-null mice exhibit gross 
and molecular phenotypes that are apparently uncompensated by normal levels of FXR1 
and FXR2.  These abnormalities in dendritic spine development could be due to a 
hypomorphic effect of a loss of FMRP; i.e. increased levels of FXR1 and/or FXR2 could 
potentially reduce these effects.  However, regulation of FXR family protein levels seems 
to be tightly regulated for a good reason.  Overexpression of dfmr also results in neuronal 
structural abnormalities (Pan et al., 2004).  An alternate hypothesis is that the 
abnormalities seen with decreased levels of FMRP are due to unique functions of FMRP, 
possibly due to loss of the RGG box and its ability to bind G-quartets.  This suggests that 
any KH2-specific roles of FMRP are fulfilled by FXR1 and/or FXR2 in the absence of 
FMRP.  The actual molecular differences in neurons that lack FMRP are likely due to 
both of the above possibilities, with the additional caveat that while FXR family members 
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share a means of association with polyribosomes, that association may result in a 
different fate for the mRNA, depending on which family member is bound. 
 While kcRNA is bound by the FXR protein family with high affinity and 
specificity, this does not preclude the possibility that additional proteins could bind 
kissing complex motifs.  In fact, Purα is shifted off polyribosomes by incubation with 
kcRNA.  This effect is independent of FMRP.  However, it is not specific to kissing 
complex RNA, since incubation with G-quartet RNA can produce a more pronounced 
shift in Purα distribution.  KH domains from several proteins (Nova1, Nova2, hnRNPE1, 
hnRNPE2, SF1 and ZBP) do not bind kcRNA in vitro (J. C. Darnell, manuscript in 
preparation.) 
Further permutations of FXR protein-containing mRNPs can result from the 
association of other proteins.  A number of FMRP-interacting proteins have been 
identified.  Some of these proteins specifically bind FMRP (e.g. CYFIP1), while others 
interact with all three family members (e.g. CYFIP2) (Schenck et al., 2001). Moreover, 
some of these interacting proteins (e.g. NUFIP1, CYFIP1, and CYFIP2) bind to the same 
N-terminal domain that mediates homodimerization and heterodimerization of FXR 
family members, potentially competing for this binding site (Bardoni et al., 1999; 
Schenck et al., 2001).  We find that KH2 binding to kissing complex RNA does not 
disrupt heterodimerization between FMRP and FXR1 or FXR2.  Thus, the variety of 
proteins that interact with FMRP through the N-terminal domain may also be associated 
with polyribosomes through FMRP.  FXR1 and FXR2 show a nine percent shift from 
heavy polyribosomes to small complexes in wild type versus FMRP knockout cerebral 
cortex lysate.  This suggests that, while FXR1 and FXR2 interact with polyribosomes 
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through direct binding of kissing complex motifs, they may also be able to bind 
FMRP:polyribosomes by means of protein-protein heterodimerization. 
Studies are ongoing on fmr1/fxr2 double knockout animals, and will provide more 
data on the functional redundancy of these proteins.  However, a homozygous fxr1-null 
mutation is lethal at birth.  Therefore, other methods are required to study what happens 
when all FXR proteins are functionally absent.  Since kcRNA specifically binds to and is 
able to compete with endogenous targets of the KH2 domains of FMRP, FXR1 and 
FXR2, artificially introduced kcRNAs have the potential to abrogate function of these 
domains.  On the other hand, gqRNA only binds FMRP.  Thus the expression of these 
RNAs in vivo represents a system by which the specific roles of FXR proteins could be 
dissected with respect to the activities of their RNA binding domains, in the context of 
wild type proteins.  The development of such a system is not trivial, due to difficulty in 
achieving sufficiently high levels of RNA decoy expression, since, to our knowledge, 
RNAs of this type are not normally produced by cells.  However, if these difficulties can 





 Jennifer Darnell provided the alignments shown in Figures 6.1 and 6.2, as well as 
the recombinant protein used in in vitro nitrocellulose binding assays. Antibodies to 
FXR1, NUFIP, CYFIP1, CYFIP2 and 83FIP were provided by Barbara Bardoni.  
Antibodies to hAgo1 and hAgo2 were provided by Tom Tuschl. 
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CHAPTER VII: GENERAL DISCUSSION 
Nova proteins are partially bound to polyribosomes   
In our studies of density gradient distributions of RNA-binding proteins in mouse 
brain, we found that approximately 10-25% of cytosolic Nova is shifted by EDTA 
treatment, supporting the hypothesis that this population of Nova proteins is associated 
with polyribosomes.  Microarray comparisons between Nova-1 wild type and knockout 
spinal cord polyribosomal mRNAs have identified possible targets of Nova.  However, 
the differences we observed were small, suggesting that translational regulation is likely 
to be a subtle process better studied through analysis of corresponding changes in the 
mRNA content of other polyribosome gradient regions such as mRNPs. Furthermore, 
none our validated Nova alternative splicing targets (Ule et al., 2003; Ule et al., 2005b) 
show a greater than two-fold change between wild type and Nova-1 knockout spinal cord 
polyribosomes.  These data represent the first biochemical assays showing a possible role 
for Nova proteins in translational control.  As such these studies provide a foundation for 
future evaluation of this role in Nova biology; they provide a general platform of data 
from which to launch more specific experiments.  While yielding some important results, 
these experiments were subject to some limitations.  First, the lack of robust changes in 
polyribosomal mRNA populations in the absence of Nova-1 emphasizes the need for 
improved signal to noise ratios when using gradient density fractionation to isolate 
polyribosomes from the central nervous system.  In essence, the presence of too many 
cell types and parts of cells (e.g. cell body vs. processes) obscures specific conclusions in 
this method.  Clearer data for mRNA targeting and localization could be obtained by 
looking at specific neuronal layers using microdissection techniques.  These experiments 
 145 
did not eliminate redundant function as a confounding variable: comparing wild type to 
Nova-1/Nova-2 double knockout mice would yield maximum differences.  Finally, 
further amplification of differences in the mRNA complement of polyribosomes can be 
achieved by measuring reciprocal changes in mRNA distribution over polyribosomal 
gradient fractionations.  One can imagine that these methods could also be used to 
analyze activity-dependent changes in mRNA association with polyribosomes in a variety 
of paradigms such as seizure induction and glycine- or GABA- receptor blockade.   
These proposed experiments could further refine our working model of Nova 
function in neurons.  As such, we have evidence that Nova proteins bind nascent RNA 
transcripts in the nucleus and influence splice site selection for nearby exons (Dredge and 
Darnell, 2003; Jensen et al., 2000a; Ule et al., 2003; Ule et al., 2006; Ule et al., 2005b).  
It is most likely that cytoplasmic Nova proteins remain associated with previously 
alternatively-spliced mRNAs as a component of the exon-exon junction complex during 
nuclear export.  At some point during cytoplasmic mRNA processing and transport, most 
Nova proteins disengage from mRNA complexes and return to the nucleus.  However, we 
have not excluded a possible role for Nova in mRNA transport and/or localization.  The 
11-22% of cytoplasmic Nova proteins that are associated with brain polyribosomes may 
merely be a remnant of the exon-exon junction complex that has survived until an initial 
round of translation in the cytoplasm.  Conversely, polyribosome-bound Nova may 
influence translational regulation of its target mRNA, perhaps by sequestering such 
mRNAs in a ribosome-loaded but inactive state, in readiness for a local signal that allows 
translation to procede. 
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A conserved role for Fragile X Mental Retardation Protein and its family members FXR1 
and FXR2 
We found that FMRP is associated with actively translating ribosomal complexes 
in mouse cerebral cortex (Stefani et al., 2004). This is in agreement with previously 
published data showing that FMRP co-sediments with polyribosomes in tissue culture 
cell lines and rat synaptosomes (Corbin et al., 1997; Eberhart et al., 1996; Feng et al., 
1997a; Feng et al., 1997b; Khandjian et al., 1996).  However, our results directly refute 
the finding that FMRP does not associate with polyribosomes in mouse brain (Zalfa et al., 
2003). 
Our microarray screens of polyribosomal mRNA for differences between FMRP 
wild type and knockout mouse cerebral cortex show a remarkable lack of significant 
differences between the two genotypes in both mRNA populations (polyribosomal and 
total).  This result contrasts with previous data identifying 251 mRNAs that show altered 
polyribosomal distribution in transformed white blood cells from individuals with fragile 
X syndrome compared to non-fragile X individuals, and 144 mRNAs differed in the total 
RNA population (31 mRNAs were present in both data sets) (Brown et al., 2001).  Of the 
few genes that show subtle changes (between 1.27- and 1.42-fold) between wild type and 
FMRP knockout polyribosomes in our data, only one, proteolipid protein (Plp), has been 
previously identified as a target for FMRP (Wang et al., 2004). Our results imply that this 
method for evaluation of FMRP control of translational status for target mRNAs may be 
limited by an insensitivity to small differences in polyribosomal distribution, that may be 
visible only with measurement of reciprocal changes between mRNA populations (i.e. 
between lighter and heavier fractions of the sucrose gradient).  In order to continue to use 
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this method for FMRP mRNA target identification, it is necessary to increase the signal 
to noise ratio by measuring these reciprocal changes or by using an animal model with a 
more severe phenotype (i.e. FMRP/FXR2 double knockout mice) to validate the subtle 
changes in mRNA-polyribosome association that we have identified in FMRP single 
knockout mice.  Finally, activity-dependent changes in the functional interaction between 
FMRP and the translational apparatus have been proposed by a number of groups 
(Greenough et al., 2001; Hou et al., 2006; Huber et al., 2002; Weiler et al., 2004).  A 
polyribosome-associated, transcriptome-wide analysis of the effect of FMRP combined 
with synaptic activity in the form of metabotropic glutamate receptor modulation or 
seizure induction could provide a more refined view of the activity-dependent actions of 
FMRP. 
We have discovered that FMRP associates with polyribosomes via binding of 
KH2 to kissing complex (loop-loop pseudoknot) RNA motifs (Darnell et al., 2005a).  
Competition with exogenous kissing complex RNAs shifts FMRP off polyribosomes.  
This interaction is sequence- and structure-specific, as a single point mutation that 
disrupts one Watson-Crick base pair between the two loops fails to bind KH2, and fails to 
compete FMRP off brain polyribosomes.  The binding of the RGG box to G-quartet RNA 
does not have an effect on polyribosomal association of FMRP in brain lysate.  These 
findings support I304N data as a model for Fragile X mental retardation syndrome, and 
suggest that new mRNA targets of FMRP KH2 require identification. In addition, these 
data pose new questions of how, where and why the KH2 and RGG box RNA-binding 
domains interact with their unique target sequences.  Do they identify separate classes of 
mRNAs, or populations that contain both types of motifs?  Do they bind sequentially; 
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perhaps one domain facilitates helicase activity that unwinds one RNA structure, thereby 
allowing the binding of the other domain?  Do they bring together RNA motifs in trans to 
effect translational regulation of via elongation or another as yet unidentified 
mechanism?  These are all questions that can be addressed in further detail using G-
quartet and kissing complex RNA sequences as tools to dissect the interactions of these 
domains. 
Our experiments demonstrated that KH2:kissing complex RNA interaction is 
conserved in the FXR protein family.  Both FXR1 and FXR2 bind kissing complex 
RNAs through KH2, and like FMRP, are effectively competed off polyribosomes by a 
similar concentration of exogenous RNA ligand.  For FXR1 and FXR2 individually, 
approximately nine percent each appear to be associated with polyribosomes through 
FMRP, as they show a subtle shift in polyribosomal distribution in FMRP knockout mice.  
However, even in the absence of FMRP, FXR1 and FXR2 do bind polyribosomes via 
KH2 interaction with kissing complex RNA.  We demonstrated that this relationship is 
specific to FXR family proteins, since the polyribosomal distributions of other RNA-
binding proteins and FMRP-interacting proteins are unaffected by kissing complex RNA.  
RNA binding by KH2 does not abrogate heterodimerization of FMRP with FXR1 and 
FXR2.  The high degree of sequence and functional conservation between the KH 
domains of the three Fragile X-related proteins is a clue to possible overlapping functions 
among these proteins and underscores the critical nature of this role.  
An argument can be made that the cellular, behavioral and cognitive phenotypes 
of fragile X mental retardation syndrome are due to a loss of FMRP RGG domain RNA-
binding activity alone, since FXR1 and FXR2 are present at normal levels in individuals 
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with fragile X syndrome.  However, the existence of a severely affected fragile X patient 
with a point mutation in KH2 contradicts this hypothesis (De Boulle et al., 1993).  I304N 
FMRP is able to bind G-quartet RNA through the RGG-box domain with wild type 
affinity (Darnell et al., 2001).  Thus, even though the KH domains of FMRP, FXR1 and 
FXR2 may share similar roles in translational regulation, the loss-of-function of FMRP 
that occurs in fragile X syndrome likely includes roles for both the KH and RGG box 
domains.  This warrants further investigation of the physiological roles of FXR family 
KH domains in translational regulation in vivo.  In order to elucidate these roles, it will be 
important to develop domain-specific loss-of-function mouse models, such as an FMRP 
knock-in allele lacking the RGG box.  Mice lacking both FMRP and FXR2 have been 
generated and show increased neurological phenotypes (Spencer et al., 2006).  The I304N 
mutation, while representing a valuable model for fragile X syndrome, does not serve as a 
robust dominant negative for all three FMRP family members, since the majority of 
FXR1 and FXR2 proteins are associated with polyribosomes in the absence of protein-
protein interactions with FMRP. Our attempts to create a KH2-specific triple functional 
knockdown system for FMRP, FXR1 and FXR2 by expression of kissing complex RNA 
decoys in vivo have been unsuccessful to date, due to difficulty expressing RNA decoys 
at a sufficient level.  However, this type of methodology represents a unique strategy to 
achieve a more insightful analysis of what appears to be a highly conserved role for FXR-
family proteins in translational control. 
Our data suggest a new model for FMRP function in neurons.  FMRP, as a 
nucleocytoplasmic shuttling protein, binds mRNAs either co-transcriptionally in the 
nucleus, during nuclear export, or once the mRNA has reached the cytoplasm.  We find 
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that FMRP-bound mRNAs cosediment with the heaviest fractions of the polyribosomal 
distribution in a sucrose gradient.  FMRP associates with polyribosomes via interaction 
between the KH2 domain and a kissing-complex RNA motif.  The RGG domain of 
FMRP may add additional specificity to this protein-mRNA interaction through a G 
quartet motif in the same mRNA.  Alternatively, it may bind a G quartet in a separate 
RNA moiety, be that microRNA, ribosomal RNA, structural non-coding RNA, or another 
mRNA.  Since FXR1 and FXR2 also associate with polyribosomes via interaction with 
kcRNA motifs, we can envision a pool of mRNAs marked, and perhaps sequestered by 
their interactions with FMRP family members.  These mRNAs are likely to be loaded 
with many ribosomes, in a state of translational repression that can be lifted on receipt of 
a local synaptic signal indicating a need for the protein products of these mRNAs.  Such a 
signal could involve phosphorylation of FMRP family members and/or a conformational 
change that unwinds these mRNP complexes and allows translation to restart. 
The Nova and Fragile X-related protein families share homology as RNA-binding 
proteins through their KH domains.  Their diversity in displaying different polyribosomal 
associations, subcellular distributions, and likely different roles in post-synaptic 
translational regulation, demonstrate the important nature of RNA-binding proteins in 
human neurologic function and disease.  Their pathophysiologic role is not necessarily 
limited to that in the diseases in which they were discovered.  For example, FXR1 has 
been described as an autoantigen in a case of scleroderma (Bolivar et al., 1998).  Of note, 
this is just one such example of how RNA-binding proteins are implicated in autoimmune 
neurological diseases.  In regard to the biology of these protein families, persistent 
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